


NINTH EDITION

# CLINICAL CHEMISTRY

Principles, Techniques, and Correlations

Michael L. Bishop | Edward P. Fody

Carleen Van Siclen | James March Mistler | Michelle Moy



NINTH EDITION

# CLINICAL CHEMISTRY

Principles, Techniques, and Correlations

**Michael L. Bishop, MS, MLS(ASCP)**

Adjunct Faculty, Medical Laboratory Scientist Program, Santa Fe College, Alachua FL  
Retired Faculty, Medical Technology Program, Duke University Medical Center, Durham, North Carolina  
Retired Program Director and University Department Chair, Medical Laboratory Science  
and Medical Laboratory Technician Program, Keiser University, Orlando, Florida

**Edward P. Fody, MD**

Clinical Professor, Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine,  
Nashville, Tennessee  
Pathologist, Holland Hospital, Holland, Michigan

**Carleen Van Siclen, MS,MLS(ASCP)<sup>CM</sup>,TS(ABB)**

Assistant Professor of Laboratory Medicine and Pathology, MCSHS Medical Laboratory Science Program  
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida

**James March Mistler, ABD, MS, MLS(ASCP)<sup>CM</sup>**

Program Director and Fulltime Lecturer, Department of Medical Laboratory Science, University of Massachusetts Dartmouth,  
North Dartmouth, Massachusetts

**Michelle Moy, MAdEd, MT(ASCP) SC**

Assistant Professor of Medical Laboratory Science, Program Director, Biomedical Science, Department of Natural Science  
and Mathematics, College of Arts and Sciences, Madonna University, Livonia, Michigan





World Headquarters  
Jones & Bartlett Learning  
25 Mall Road  
Burlington, MA 01803  
978-443-5000  
info@jblearning.com  
www.jblearning.com



Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, [www.jblearning.com](http://www.jblearning.com).

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to [specialsales@jblearning.com](mailto:specialsales@jblearning.com).

Copyright © 2023 by Jones & Bartlett Learning, LLC, an Ascend Learning Company

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC, and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. *Clinical Chemistry: Principles, Techniques, and Correlations, Ninth Edition* is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious but are used for instructional purposes only.

23886-0

#### Production Credits

Vice President, Product Management: Marisa R. Urbano  
Vice President, Content Strategy and Implementation:  
Christine Emerton  
Director, Product Management: Matthew Kane  
Product Manager: William Lawrensen  
Content Strategist: Carol Brewer Guerrero  
Content Coordinator: Samantha Gillespie  
Director, Project Management and Content Services: Karen Scott  
Manager, Project Management: Kristen Rogers  
Project Manager: Daniel Stone  
Senior Digital Project Specialist: Angela Dooley

Marketing Manager: Mark Adamiak  
Composition: Exela Technologies  
Project Management: Exela Technologies  
Cover Design: Kristin Parker  
Senior Media Development Editor: Troy Liston  
Rights & Permissions Manager: John Rusk  
Rights Specialist: Rebecca Damon  
Rights Specialist: Liz Kincaid  
Cover Image (Title Page, Part Opener, Chapter Opener):  
© Yurchanka Siarhei/Shutterstock  
Printing and Binding: LSC Communications

#### Library of Congress Cataloging-in-Publication Data

Names: Bishop, Michael L., editor. | Fody, Edward P., editor. | Siclen, Carleen Van, editor. | Mistler, James March, editor. | Moy, Michelle, editor.  
Title: Clinical chemistry: principles, techniques, and correlations / [edited by] Michael L. Bishop, Edward P. Fody, Carleen Van Siclen, James March Mistler, Michelle Moy.  
Other titles: Clinical chemistry (Bishop)  
Description: Ninth edition. | Burlington, MA : Jones & Bartlett Learning, [2023] | Includes bibliographical references and index.  
Identifiers: LCCN 2021034082 | ISBN 9781284238860 (paperback)  
Subjects: LCSH: Clinical chemistry.  
Classification: LCC RB40 .C576 2023 | DDC 616.07/56—dc23  
LC record available at <https://lcn.loc.gov/2021034082>

6048

Printed in the United States of America

26 25 24 23 22 10 9 8 7 6 5 4 3 2 1



# Disclaimer

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner; the clinical treatments described and recommended may not be considered absolute and universal recommendations.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with the

current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Health Canada clearance for limited use in restricted research settings. It is the responsibility of the healthcare provider to ascertain the Health Canada status of each drug or device planned for use in his or her clinical practice.



# Brief Contents

<b>Foreword</b>	<b>xviii</b>
<b>Preface</b>	<b>xx</b>
<b>New to This Edition</b>	<b>xxii</b>
<b>Acknowledgments</b>	<b>xxviii</b>
<b>Contributors</b>	<b>xxix</b>
<b>Ancillary Contributors</b>	<b>xxxii</b>
<b>Reviewers</b>	<b>xxxiii</b>

## **PART 1 Basic Principles and Practice in Clinical Chemistry 1**

<b>CHAPTER 1</b>	<b>Basic Principles and Practices of Clinical Chemistry</b> . . . . .	<b>2</b>
<b>CHAPTER 2</b>	<b>Laboratory Safety and Regulations</b> . . . . .	<b>38</b>
<b>CHAPTER 3</b>	<b>Quality Management in the Clinical Laboratory</b> . . . . .	<b>57</b>
<b>CHAPTER 4</b>	<b>Analytic Techniques</b> . . . . .	<b>90</b>
<b>CHAPTER 5</b>	<b>Clinical Chemistry Automation</b> . . . . .	<b>129</b>

## **PART 2 Analytic Procedures and Clinical Correlation 161**

<b>CHAPTER 6</b>	<b>Proteins and Heme Derivatives</b> . . . . .	<b>162</b>
<b>CHAPTER 7</b>	<b>Nonprotein Nitrogen Compounds</b> . . . . .	<b>207</b>
<b>CHAPTER 8</b>	<b>Enzymes</b> . . . . .	<b>225</b>
<b>CHAPTER 9</b>	<b>Carbohydrates</b> . . . . .	<b>260</b>
<b>CHAPTER 10</b>	<b>Lipids and Lipoproteins</b> . . . . .	<b>286</b>
<b>CHAPTER 11</b>	<b>Electrolytes</b> . . . . .	<b>316</b>
<b>CHAPTER 12</b>	<b>Blood Gases, pH, and Buffer Systems</b> . . . . .	<b>348</b>

<b>PART 3</b>	<b>Endocrinology and Clinical Correlation</b>	<b>369</b>
CHAPTER 13	Basic Endocrinology . . . . .	370
CHAPTER 14	Thyroid Function . . . . .	395
CHAPTER 15	Hypothalamic and Pituitary Function . . . . .	410
CHAPTER 16	Adrenal Function . . . . .	426
CHAPTER 17	Gonadal Function . . . . .	447
CHAPTER 18	Parathyroid Function . . . . .	469
<b>PART 4</b>	<b>Organ Systems and Clinical Correlation</b>	<b>485</b>
CHAPTER 19	Liver Function . . . . .	486
CHAPTER 20	Cardiac Function . . . . .	517
CHAPTER 21	Renal Function . . . . .	539
CHAPTER 22	Pancreatic Function . . . . .	566
<b>PART 5</b>	<b>Specialty Areas of Clinical Chemistry</b>	<b>579</b>
CHAPTER 23	Body Fluid Analysis . . . . .	580
CHAPTER 24	Pregnancy and Prenatal Testing . . . . .	601
CHAPTER 25	Therapeutic Drug Monitoring . . . . .	622
CHAPTER 26	Toxicology . . . . .	646
CHAPTER 27	Trace Elements, Toxic Elements, and Vitamins . . . . .	669
CHAPTER 28	Tumor Markers . . . . .	703
CHAPTER 29	Point-of-Care Testing . . . . .	724
CHAPTER 30	Newborn and Pediatric Clinical Chemistry . . . . .	734
CHAPTER 31	Geriatric Clinical Chemistry . . . . .	760
	<b>Appendix: Reference Ranges</b>	<b>781</b>
	<b>Glossary</b>	<b>789</b>
	<b>Index</b>	<b>805</b>

# Contents

<b>Foreword</b> .....	<b>xviii</b>
<b>Preface</b> .....	<b>xx</b>
<b>New to This Edition</b> .....	<b>xxii</b>
<b>Acknowledgments</b> .....	<b>xxviii</b>
<b>Contributors</b> .....	<b>xxix</b>
<b>Ancillary Contributors</b> .....	<b>xxxii</b>
<b>Reviewers</b> .....	<b>xxxiii</b>

## PART 1 Basic Principles and Practice in Clinical Chemistry

1

### CHAPTER 1 Basic Principles and Practices of Clinical Chemistry . . . . . 2

*Kathryn Dugan and Elizabeth Warning*

Units of Measure .....	4
Reagents .....	6
Chemicals .....	6
Reference Materials .....	7
Water Specifications .....	7
Solution Properties .....	8
Concentration .....	8
Colligative Properties .....	9
Redox Potential .....	10
Conductivity .....	10
pH and Buffers .....	10
Laboratory Equipment .....	11
Heating Units .....	11
Glassware and Plasticware .....	11
Desiccators and Desiccants .....	17
Balances .....	17
Centrifuges .....	18
Laboratory Mathematics and Calculations . . .	20
Significant Figures .....	20
Logarithms .....	20
Concentration .....	21
Dilutions .....	24
Simple Dilutions .....	25

Serial Dilutions .....	26
Water of Hydration .....	27
Graphing and Beer's Law .....	28
Specimen Collection and Handling .....	30
Types of Samples .....	30
Sample Processing .....	32
Sample Variables .....	33
Chain of Custody .....	34
Electronic and Paper Reporting of Results .....	35

### CHAPTER 2 Laboratory Safety and Regulations. . . . . 38

*Brandy Greenhill*

Laboratory Safety and Regulations .....	39
Occupational Safety and Health Act .....	39
Other Regulations and Guidelines .....	41
Safety Awareness for Clinical Laboratory Personnel .....	41
Safety Responsibility .....	41
Signage and Labeling .....	42
Safety Equipment .....	43
Chemical Fume Hoods and Biosafety Cabinets .....	43
Chemical Storage Equipment .....	44
PPE and Hygiene .....	44
Biologic Safety .....	45
General Considerations .....	45
Spills .....	45
Bloodborne Pathogens .....	46
Airborne Pathogens .....	46
Shipping .....	46
Chemical Safety .....	46
Hazard Communication .....	46
Safety Data Sheet .....	47
OSHA Laboratory Standard .....	47
Toxic Effects from Hazardous Substances .....	47
Storage and Handling of Chemicals .....	48
Radiation Safety .....	49
Environmental Protection .....	49
Personal Protection .....	49

Fire Safety . . . . .	50
The Chemistry of Fire . . . . .	50
Classification of Fires . . . . .	50
Types and Applications of Fire Extinguishers . . . . .	51
Control of Other Hazards . . . . .	52
Electrical Hazards . . . . .	52
Compressed Gas Hazards . . . . .	52
Cryogenic Materials Hazards . . . . .	52
Mechanical Hazards . . . . .	52
Ergonomic Hazards . . . . .	53
Disposal of Hazardous Materials . . . . .	53
Chemical Waste . . . . .	53
Radioactive Waste . . . . .	53
Biohazardous Waste . . . . .	53
Accident Documentation and Investigation . . . . .	54
<b>CHAPTER 3 Quality Management in the Clinical Laboratory . . . . .</b>	<b>57</b>
<i>Yun L. Trull, Michael W. Rogers, Cyndy B. Levtzow, Matthew P. A. Henderson, Christopher R. McCudden, and Monte S. Willis</i>	
Basic Concepts . . . . .	59
Descriptive Statistics: Measures of Center, Spread, and Shape . . . . .	59
Measurement of Precision . . . . .	62
Descriptive Statistics of Groups of Paired Observations . . . . .	64
Measurement of Bias . . . . .	66
Inferential Statistics . . . . .	68
Quality Control and Quality Improvement . . . . .	69
QC Charts . . . . .	70
Operation of a QC System . . . . .	71
Multi-Rules Rule! . . . . .	73
Proficiency Testing . . . . .	74
Lean Six Sigma . . . . .	76
Quality Assessment . . . . .	76
Individual Quality Control Program (IQCP): An Option to Streamline QCP . . . . .	77
Reference Range Studies . . . . .	77
Establishing Reference Ranges . . . . .	79
Determining Whether to Establish or Transfer and Verify Reference Ranges . . . . .	79
Data Analysis to Establish a Reference Range . . . . .	80
Data Analysis to Transfer and Verify a Reference Range . . . . .	82
Method Evaluation . . . . .	83
Regulatory Aspects of Method Evaluation . . . . .	83
Allowable Analytical Error . . . . .	84
Method Evaluation Acceptance Criteria . . . . .	84
Diagnostic Efficiency . . . . .	85
Measures of Diagnostic Efficiency . . . . .	85

## CHAPTER 4 Analytic Techniques . . . 90

*Karen K. Apolloni*

Spectrophotometry . . . . .	91
Beer's Law . . . . .	92
Spectrophotometric Instruments . . . . .	94
Components of a Spectrophotometer . . . . .	94
Spectrophotometer Quality Assurance . . . . .	97
Atomic Absorption Spectrophotometry . . . . .	98
Fluorometry . . . . .	99
Fluorometry Instrumentation . . . . .	100
Fluorescence Polarization . . . . .	100
Advantages and Disadvantages of Fluorometry . . . . .	101
Chemiluminescence . . . . .	101
Turbidimetry . . . . .	102
Nephelometry . . . . .	102
Laser Applications . . . . .	102
Electrochemistry . . . . .	102
Galvanic and Electrolytic Cells . . . . .	103
Half-Cells . . . . .	103
Ion-Selective Electrodes . . . . .	103
pH Electrodes . . . . .	103
Gas-Sensing Electrodes . . . . .	105
Enzyme Electrodes . . . . .	107
Coulometric Titration . . . . .	107
Anodic Stripping Voltammetry . . . . .	107
Electrophoresis . . . . .	107
Procedure . . . . .	108
Support Materials . . . . .	109
Treatment and Application of Sample . . . . .	109
Detection and Quantitation . . . . .	109
Electroendosmosis . . . . .	109
Isoelectric Focusing . . . . .	110
Immunofixation Electrophoresis . . . . .	110
Capillary Electrophoresis . . . . .	110
Two-Dimensional Electrophoresis . . . . .	111
Osmometry . . . . .	111
Freezing Point Osmometer . . . . .	112
Newer Optical Techniques . . . . .	112
Chromatography . . . . .	113
Modes of Separation . . . . .	113
Chromatographic Procedures . . . . .	115
High-Performance Liquid Chromatography . . . . .	115
Gas Chromatography . . . . .	117
Mass Spectrometry . . . . .	118
Sample Introduction and Ionization . . . . .	119
Mass Spectrometer Analyzer . . . . .	121
Detector . . . . .	124



Applications of MS in the Clinical Laboratory . . . . .	124
Small Molecule Analysis . . . . .	124
Mass Spectrometry in Proteomics and Pathogen Identification . . . . .	126
Mass Spectrometry at the Point of Care . . . . .	127
<b>CHAPTER 5 Clinical Chemistry Automation . . . . .</b>	<b>129</b>
<i>Nikola A. Baumann and Brooke M. Katzman</i>	
History and Evolution of Automated Analyzers . . . . .	130
Driving Forces and Benefits of Automation . . . . .	131
Steps in Automated Analysis . . . . .	135
Specimen Preparation and Identification . . . . .	135
Specimen Measurement and Delivery . . . . .	136
Reagent Systems and Delivery . . . . .	138
Chemical Reaction Phase . . . . .	138
Measurement Phase . . . . .	140
Signal Processing and Data Handling . . . . .	141
Additional Considerations for Automated Immunoassays . . . . .	143
Immunoassay Basics . . . . .	143
Turbidimetry and Nephelometry . . . . .	144
Labeled Immunoassays . . . . .	145
Total Laboratory Automation . . . . .	153
Preanalytic Phase . . . . .	153
Analytic Phase . . . . .	156
Postanalytic Phase . . . . .	156
Future Trends in Automation . . . . .	157

## PART 2 Analytic Procedures and Clinical Correlation 161

<b>CHAPTER 6 Proteins and Heme Derivatives . . . . .</b>	<b>162</b>
<i>Takara L. Blamires and Kristina Jackson Behan</i>	
Amino Acids . . . . .	164
Overview . . . . .	164
Basic Structure . . . . .	164
Metabolism . . . . .	164
Classification . . . . .	166
Aminoacidopathies . . . . .	169
Methods of Analysis . . . . .	169
Proteins . . . . .	169
Overview . . . . .	169
Basic Structure . . . . .	169
General Chemical Properties . . . . .	171
Synthesis . . . . .	172

Catabolism and Nitrogen Balance . . . . .	173
Hormonal Regulation of Protein Metabolism . . . . .	174
Classification . . . . .	174
Plasma Proteins . . . . .	175
Prealbumin . . . . .	175
Albumin . . . . .	177
Globulins . . . . .	178
Other Proteins of Clinical Significance . . . . .	184
Troponin . . . . .	184
Natriuretic Peptides . . . . .	184
Fibronectin . . . . .	184
Cross-Linked C-Telopeptide . . . . .	184
Cystatin C . . . . .	184
Plasma Total Protein Abnormalities . . . . .	185
Hypoproteinemia . . . . .	185
Hyperproteinemia . . . . .	185
Methods of Analysis . . . . .	185
Sample Requirements . . . . .	186
Total Protein . . . . .	186
Albumin . . . . .	187
Immunochemical Assays . . . . .	188
Electrophoresis . . . . .	188
Proteins in Other Body Fluids . . . . .	194
Urine . . . . .	194
Cerebrospinal Fluid . . . . .	196
Hemoglobin . . . . .	198
Synthesis and Degradation of Hemoglobin . . . . .	198
Myoglobin . . . . .	199
Heme . . . . .	199
Synthesis of Heme . . . . .	200
Disorders of Heme Biosynthesis . . . . .	200
Clinical Application . . . . .	202
Analytical Methods . . . . .	202

## CHAPTER 7 Nonprotein Nitrogen Compounds . . . . . 207

*Shawn H.W. Luby*

Urea . . . . .	208
Biochemistry . . . . .	209
Clinical Application . . . . .	209
Analytical Methods . . . . .	210
Pathophysiology . . . . .	211
Uric Acid . . . . .	212
Biochemistry . . . . .	212
Clinical Application . . . . .	212
Analytical Methods . . . . .	213
Pathophysiology . . . . .	214
Creatinine/Creatine . . . . .	215
Biochemistry . . . . .	215
Clinical Application . . . . .	215

Analytical Methods . . . . .	218
Pathophysiology . . . . .	220
<b>Ammonia . . . . .</b>	<b>220</b>
Biochemistry . . . . .	220
Clinical Application . . . . .	220
Analytical Methods . . . . .	221
Pathophysiology . . . . .	222
<b>CHAPTER 8 Enzymes . . . . .</b>	<b>225</b>
<i>Donna J. Spannaus-Martin</i>	
General Properties and Definitions . . . . .	226
Enzyme Classification and Nomenclature . . . . .	227
Enzyme Kinetics . . . . .	229
Enzyme Catalysis . . . . .	229
Factors That Influence Enzymatic Reactions . . . . .	230
Measurement of Enzyme Activity . . . . .	233
Calculation of Enzyme Activity . . . . .	235
Measurement of Enzyme Mass . . . . .	235
Enzymes as Reagents . . . . .	235
Enzymes of Clinical Significance . . . . .	236
Creatine Kinase . . . . .	236
Lactate Dehydrogenase . . . . .	242
Aspartate Aminotransferase . . . . .	243
Alanine Aminotransferase . . . . .	244
Alkaline Phosphatase . . . . .	245
Acid Phosphatase . . . . .	247
$\gamma$ -Glutamyltransferase . . . . .	249
5'-Nucleotidase . . . . .	250
Amylase . . . . .	251
Lipase . . . . .	253
Glucose-6-Phosphate Dehydrogenase . . . . .	254
Macroenzymes . . . . .	254
Drug-Metabolizing Enzymes . . . . .	255
<b>CHAPTER 9 Carbohydrates . . . . .</b>	<b>260</b>
<i>Vicki S. Freeman</i>	
General Description of Carbohydrates . . . . .	262
Classification of Carbohydrates . . . . .	262
Stereoisomers . . . . .	263
Monosaccharides, Disaccharides, and Polysaccharides . . . . .	263
Chemical Properties of Carbohydrates . . . . .	264
Glucose Metabolism . . . . .	264
Fate of Glucose . . . . .	265
Regulation of Carbohydrate Metabolism . . . . .	267
Hyperglycemia . . . . .	268
Diabetes Mellitus . . . . .	268
Pathophysiology of Diabetes Mellitus . . . . .	271
Criteria for Testing for Prediabetes and Diabetes . . . . .	271
Criteria for the Diagnosis of Diabetes Mellitus . . . . .	272
Criteria for the Testing and Diagnosis of GDM. . . . .	273
Hypoglycemia . . . . .	275
Genetic Defects in Carbohydrate Metabolism . . . . .	276
Role of the Laboratory in Differential Diagnosis and Management of Patients with Glucose Metabolic Alterations . . . . .	277
Methods of Glucose Measurement . . . . .	277
Self-Monitoring of Blood Glucose . . . . .	279
Glucose Tolerance and 2-Hour Postprandial Tests . . . . .	279
Glycosylated Hemoglobin/HbA1c . . . . .	280
Ketones . . . . .	282
Albuminuria . . . . .	283
Islet Autoantibody, Insulin Testing, and C-Peptide Testing . . . . .	283
<b>CHAPTER 10 Lipids and Lipoproteins . . . . .</b>	<b>286</b>
<i>Kathleen M. Kenwright</i>	
Lipid Chemistry . . . . .	288
Fatty Acids . . . . .	288
Triglycerides . . . . .	289
Phospholipids . . . . .	289
Cholesterol . . . . .	290
General Lipoprotein Structure . . . . .	290
Chylomicrons . . . . .	292
Very-Low-Density Lipoprotein . . . . .	292
Intermediate-Density Lipoproteins . . . . .	292
Low-Density Lipoproteins . . . . .	293
Lipoprotein (a) . . . . .	293
High-Density Lipoproteins . . . . .	293
Lipoprotein X . . . . .	294
Lipoprotein Physiology and Metabolism . . . . .	294
Lipid Absorption . . . . .	294
Exogenous Pathway . . . . .	295
Endogenous Pathway . . . . .	295
Reverse Cholesterol Transport Pathway . . . . .	296
Lipid and Lipoprotein Population Distributions . . . . .	296
National Cholesterol Education Program . . . . .	297
Dyslipidemia and Children . . . . .	297
National Heart, Lung, and Blood Institute . . . . .	298
Diagnosis and Treatment of Lipid Disorders . . . . .	300
Arteriosclerosis . . . . .	300
Hyperlipoproteinemia . . . . .	302
Hypercholesterolemia . . . . .	302
PCSK9 . . . . .	303
Hypertriglyceridemia . . . . .	304
Combined Hyperlipidemia . . . . .	304
Lp(a) Elevation . . . . .	305
Non-HDL Cholesterol . . . . .	305

Hypobetalipoproteinemia . . . . . 305

Hypoalphalipoproteinemia . . . . . 305

**Lipid and Lipoprotein Analyses . . . . . 306**

    Lipid Measurement . . . . . 306

    Cholesterol Measurement . . . . . 306

    Triglyceride Measurement . . . . . 307

    Lipoprotein Methods . . . . . 308

    HDL Methods . . . . . 309

    LDL Methods . . . . . 309

    Apolipoprotein Methods . . . . . 310

    Phospholipid Measurement . . . . . 310

    Fatty Acid Measurement . . . . . 311

**Standardization of Lipid and Lipoprotein Assays . . . . . 311**

    Precision . . . . . 311

    Accuracy . . . . . 311

    Matrix Interactions . . . . . 311

    CDC Cholesterol Reference Method Laboratory Network . . . . . 312

    Analytic Performance Goals . . . . . 312

    Quality Control . . . . . 312

    Specimen Collection . . . . . 312

**CHAPTER 11 Electrolytes . . . . . 316**

*James March Mistler*

**Water . . . . . 317**

    Osmolality . . . . . 318

**The Electrolytes . . . . . 321**

    Sodium . . . . . 321

    Potassium . . . . . 325

    Chloride . . . . . 329

    Bicarbonate . . . . . 330

    Calcium . . . . . 331

    Magnesium . . . . . 336

    Phosphate . . . . . 341

    Lactate . . . . . 342

**Anion Gap . . . . . 344**

**Electrolytes and Renal Function . . . . . 345**

**CHAPTER 12 Blood Gases, pH, and Buffer Systems . . . . . 348**

*Kyle B. Riding*

**Acid–Base Balance . . . . . 349**

    Maintenance of H<sup>+</sup> . . . . . 349

    Buffer Systems: Regulation of H<sup>+</sup> and the Henderson-Hasselbalch Equation . . . . . 350

    Regulation of Acid–Base Balance: Lungs and Kidneys (Transport of Carbon Dioxide) . . . . . 350

**Assessment of Acid–Base Homeostasis . . . . . 352**

    The Bicarbonate Buffering System . . . . . 352

    Acid–Base Disorders: Acidosis and Alkalosis . . . . . 353

    Determining Patient Acid–Base Status . . . . . 356

**Oxygen and Gas Exchange . . . . . 356**

    Oxygen and Carbon Dioxide . . . . . 356

    Oxygen Transport . . . . . 358

    Assessment of a Patient’s Oxygen Status . . . . . 358

    Hemoglobin–Oxygen Dissociation . . . . . 359

**Measurement . . . . . 360**

    Blood Gas Analyzers: pH, pCO<sub>2</sub>, and pO<sub>2</sub> . . . . . 360

    Measurement of pO<sub>2</sub> . . . . . 360

    Measurement of pH and pCO<sub>2</sub> . . . . . 361

    Types of Sensors . . . . . 361

    Calibration . . . . . 362

    Correction for Temperature . . . . . 362

    Calculated Parameters . . . . . 362

    Spectrophotometric Determination of Oxygen Saturation (CO-Oximetry) . . . . . 363

**Quality Assurance . . . . . 364**

    Preanalytic Considerations . . . . . 364

    Analytic Assessments: Quality Control and Proficiency Testing . . . . . 366

**PART 3 Endocrinology and Clinical Correlation 369**

**CHAPTER 13 Basic Endocrinology . . . . . 370**

*Scott Moore*

**Hormone Classification . . . . . 372**

    Amine . . . . . 372

    Peptide . . . . . 372

    Protein . . . . . 372

    Glycoprotein . . . . . 375

    Steroid . . . . . 375

    Fatty Acid . . . . . 375

**Introduction to Hormones . . . . . 376**

    Growth Hormone (GH) . . . . . 376

    Adrenocorticotrophic Hormone (ACTH) and the Adrenal Cortical Hormones . . . . . 377

    Follicle Stimulating Hormone and Luteinizing Hormone . . . . . 378

    Prolactin (PRL) . . . . . 378

    Androgens . . . . . 379

    Progesterone . . . . . 379

    Estrogens/Estradiol/Estriol . . . . . 380

    Catecholamines . . . . . 380

    Thyroid Hormone (T<sub>3</sub>, T<sub>4</sub>) and Thyroid Stimulating Hormone (TSH) . . . . . 381

    Posterior Pituitary Hormones . . . . . 383

    Calcitonin and Procalcitonin . . . . . 384

    Parathyroid Hormone (PTH) . . . . . 384

    Insulin . . . . . 384

    Glucagon . . . . . 384

Gastrin and Secretin . . . . . 385

Human Chorionic Gonadotropin (hCG) . . . . . 385

Serotonin/5-hydroxyindolacetic Acid (5-HIAA) . . . . . 385

**Hormone Metabolism . . . . . 385**

    Alcohol Consumption . . . . . 386

    Adrenal Steroid Hormone Synthesis . . . . . 386

**Mechanisms of Elimination . . . . . 386**

**Hormone Transport . . . . . 386**

    Solubility . . . . . 386

    Carrier Proteins . . . . . 386

    Micelles . . . . . 386

**Feedback Mechanisms . . . . . 387**

    Negative Feedback Mechanisms . . . . . 388

    Positive Feedback Mechanisms . . . . . 388

**Primary, Secondary, and Tertiary Disorders . . . . . 388**

**Other Factors That Affect Hormone Levels . . . . . 389**

    Emotional Stress . . . . . 389

    Time of Day . . . . . 389

    Menstrual Cycle . . . . . 390

    Menopause . . . . . 390

    Food Intake/Diet . . . . . 391

    Drugs . . . . . 391

**CHAPTER 14 Thyroid Function . . . . . 395**

*Yukari Nishizawa-Brennen*

**The Thyroid . . . . . 396**

    Thyroid Anatomy and Development . . . . . 396

    Thyroid Hormone Synthesis . . . . . 396

    Protein Binding of Thyroid Hormone . . . . . 398

    Control of Thyroid Function . . . . . 398

    Actions of Thyroid Hormones . . . . . 399

**Tests for Thyroid Function . . . . . 399**

    Thyroid-Stimulating Hormone . . . . . 399

    Thyroxine (T<sub>4</sub>) . . . . . 400

    Triiodothyronine (T<sub>3</sub>) . . . . . 400

    Free Thyroxine (FT<sub>4</sub>) . . . . . 400

    Free Triiodothyronine (FT<sub>3</sub>) . . . . . 400

    Thyroglobulin Antibody . . . . . 401

    Thyroperoxidase Antibody . . . . . 402

    Thyrotropin Receptor Antibody . . . . . 402

**Other Tools for Thyroid Evaluation . . . . . 402**

    Nuclear Medicine Evaluation . . . . . 402

    Thyroid Ultrasound . . . . . 403

    Fine-Needle Aspiration . . . . . 403

**Disorders of the Thyroid . . . . . 403**

    Hypothyroidism . . . . . 403

    Thyrotoxicosis . . . . . 405

    Hyperthyroidism . . . . . 405

    Toxic Adenoma and Multinodular Goiter . . . . . 407

Drug-Induced Thyroid Dysfunction . . . . . 407

    Amiodarone-Induced Thyroid Disease . . . . . 407

Subacute Thyroiditis . . . . . 407

Nonthyroidal Illness . . . . . 408

Thyroid Nodules . . . . . 408

**CHAPTER 15 Hypothalamic and Pituitary Function . . . . . 410**

*Stephanie L. Jacobson*

**Embryology and Anatomy . . . . . 411**

**Functional Aspects of the Hypothalamic–Hypophyseal Unit . . . . . 412**

**Pituitary Tumors . . . . . 413**

**Hypophysiotropic or Hypothalamic Hormones . . . . . 413**

**Anterior Pituitary Hormones . . . . . 414**

**Growth Hormone . . . . . 415**

    Actions of GH . . . . . 415

    Testing . . . . . 416

    GH Excess . . . . . 417

    GH Deficiency . . . . . 418

**Prolactin . . . . . 418**

    Prolactinoma . . . . . 419

    Other Causes of Hyperprolactinemia . . . . . 419

    Clinical Evaluation of Hyperprolactinemia . . . . . 419

    Management of Prolactinoma . . . . . 419

    Idiopathic Galactorrhea . . . . . 420

**Hypopituitarism . . . . . 420**

    Etiology of Hypopituitarism . . . . . 420

    Treatment of Panhypopituitarism . . . . . 421

**Posterior Pituitary Hormones . . . . . 421**

    Oxytocin . . . . . 422

    Arginine Vasopressin . . . . . 422

**CHAPTER 16 Adrenal Function . . . . . 426**

*Stephanie L. Jacobson*

**Embryology and Anatomy . . . . . 427**

**The Adrenal Cortex . . . . . 428**

    Glucocorticoid Physiology . . . . . 428

    Cortex Steroidogenesis . . . . . 428

    Congenital Adrenal Hyperplasia . . . . . 429

**Primary Aldosteronism . . . . . 430**

    Etiology . . . . . 431

    Diagnosis . . . . . 431

    Treatment . . . . . 431

**Adrenal Insufficiency . . . . . 431**

    Symptoms . . . . . 432

    Diagnosis . . . . . 432

    Treatment . . . . . 433

    Isolated Hypoaldosteronism . . . . . 433

Hypercortisolism (Cushing’s Syndrome) . . . . . 434  
 Etiology . . . . . 434  
 Diagnosis . . . . . 434  
 Treatment . . . . . 436  
**Adrenal Androgens . . . . . 437**  
 Androgen Excess . . . . . 438  
 Diagnosis . . . . . 438  
 Treatment . . . . . 438  
**The Adrenal Medulla . . . . . 439**  
 Embryology . . . . . 439  
 Biosynthesis, Storage, and Secretion of  
 Catecholamines . . . . . 439  
 Metabolism and Excretion of Catecholamines . . . 440  
**Pheochromocytoma and Paraganglioma . . . 440**  
 Epidemiology . . . . . 441  
 Clinical Presentation . . . . . 441  
 Diagnosis . . . . . 441  
 Result Interpretation . . . . . 442  
 Treatment . . . . . 443  
**Adrenal Incidentaloma . . . . . 443**

**CHAPTER 17 Gonadal Function . . . 447**

*Jane R. Semler*

**The Testes . . . . . 448**  
 Functional Anatomy of the Male  
 Reproductive Tract . . . . . 448  
 Physiology of the Testicles . . . . . 449  
 Disorders of Sexual Development and  
 Testicular Hypofunction . . . . . 451  
 Diagnosis of Hypogonadism . . . . . 454  
 Testosterone Replacement Therapy . . . . . 455  
 Monitoring Testosterone Replacement Therapy . . 456  
**The Ovaries . . . . . 456**  
 Early Ovarian Development . . . . . 456  
 Functional Anatomy of the Ovaries . . . . . 458  
 Hormonal Production by the Ovaries . . . . . 459  
 The Menstrual Cycle . . . . . 459  
 Hormonal Control of Ovulation . . . . . 460  
 Pubertal Development in the Female . . . . . 460  
 Precocious Sexual Development . . . . . 460  
 Menstrual Cycle Abnormalities . . . . . 460  
 Evaluation of Female Infertility . . . . . 462  
 Hirsutism . . . . . 463  
 Estrogen Replacement Therapy . . . . . 464

**CHAPTER 18 Parathyroid  
 Function . . . . . 469**

*Rebecca Silva*

**Parathyroid Glands . . . . . 470**  
 Parathyroid Hormone . . . . . 470  
 Vitamin D . . . . . 471

Effects of the Parathyroid Hormone . . . . . 472  
 GI Regulation . . . . . 473  
 Role of Kidneys . . . . . 473  
 Bone Physiology . . . . . 474  
**Parathyroid Disorders . . . . . 475**  
 Primary Hyperparathyroidism . . . . . 475  
 Secondary Hyperparathyroidism . . . . . 478  
 Secondary and Tertiary Hyperparathyroidism  
 in Renal Failure . . . . . 478  
 Familial Hypocalciuric Hypercalcemia . . . . . 479  
 Hyperthyroidism . . . . . 480  
 Addison’s Disease . . . . . 480  
 Medications That Cause Hypercalcemia . . . . . 480  
 Hypervitaminosis . . . . . 480  
 Parathyroid Hormone–Related Protein . . . . . 480  
 Hypoparathyroidism . . . . . 480  
**Metabolic Bone Diseases . . . . . 481**  
 Rickets and Osteomalacia . . . . . 481  
 Osteoporosis . . . . . 482

**PART 4 Organ Systems  
 and Clinical  
 Correlation 485**

**CHAPTER 19 Liver Function . . . . . 486**

*Janelle M. Chiasera*

**Anatomy . . . . . 487**  
 Gross Anatomy . . . . . 487  
 Microscopic Anatomy . . . . . 489  
**Biochemical Functions . . . . . 489**  
 Excretory and Secretory Functions . . . . . 489  
 Metabolism . . . . . 490  
 Detoxification and Drug Metabolism . . . . . 491  
**Liver Function Alterations During  
 Disease . . . . . 492**  
 Jaundice . . . . . 492  
 Cirrhosis . . . . . 494  
 Tumors . . . . . 495  
 Reye’s Syndrome . . . . . 496  
 Drug- and Alcohol-Related Disorders . . . . . 496  
**Assessment of Liver Function/Liver  
 Function Tests . . . . . 497**  
 Bilirubin . . . . . 497  
**Methods . . . . . 499**  
 Urobilinogen in Urine and Feces . . . . . 500  
 Serum Bile Acids . . . . . 501  
 Enzymes . . . . . 501  
 Tests Measuring Hepatic Synthetic Ability . . . . . 502  
 Tests Measuring Nitrogen Metabolism . . . . . 503  
 Hepatitis . . . . . 503

**CHAPTER 20 Cardiac Function . . . 517**

*Teresa A. Mortier*

Pathophysiology of Atherosclerosis . . . . . 518

Cardiac Ischemia, Angina,  
and Heart Attacks . . . . . 521

Markers of Cardiac Damage . . . . . 523

    Initial Markers of Cardiac Damage . . . . . 523

    Cardiac Troponins . . . . . 524

    Myoglobin . . . . . 527

Cardiac Injury . . . . . 527

Cardiac Biomarkers in Heart Failure . . . . . 528

Diagnosis and Risk Stratification  
of Heart Failure . . . . . 529

    Cardiac Troponins . . . . . 530

Markers of Coronary Heart Disease Risk  
and Plaque Instability . . . . . 530

    C-Reactive Protein . . . . . 530

    Homocysteine . . . . . 531

Markers of Pulmonary Embolism . . . . . 532

    Use of D-Dimer Detection in PE . . . . . 534

    Value of Assaying Troponin  
    and BNP in Acute PE . . . . . 534

Coronary Heart Disease . . . . . 534

**CHAPTER 21 Renal Function . . . . . 539**

*Peter O'Brien*

Renal Anatomy . . . . . 540

    Renal Physiology . . . . . 542

    Glomerular Filtration . . . . . 542

    Tubular Function . . . . . 543

    Elimination of Nonprotein Nitrogen  
    Compounds . . . . . 545

    Water, Electrolyte, and Acid–Base Homeostasis . . . . . 546

    Endocrine Function . . . . . 548

Analytic Procedures . . . . . 548

    Creatinine Clearance . . . . . 548

    Estimated GFR . . . . . 549

    Cystatin C . . . . . 550

$\beta_2$ -Microglobulin . . . . . 550

    Myoglobin . . . . . 550

    Albuminuria . . . . . 551

    Neutrophil Gelatinase–Associated Lipocalin . . . . . 551

    NephroCheck . . . . . 551

    Urinalysis . . . . . 551

Pathophysiology . . . . . 556

    Glomerular Diseases . . . . . 556

    Tubular Diseases . . . . . 556

    Urinary Tract Infection/Obstruction . . . . . 557

    Renal Calculi . . . . . 557

    Renal Failure . . . . . 558

**CHAPTER 22 Pancreatic  
Function . . . . . 566**

*Gerald D. Redwine, John E. Lee Sang,  
and Amanda Rivera-Begeman*

Physiology of Pancreatic Function . . . . . 567

Diseases of the Pancreas . . . . . 569

Tests of Pancreatic Function . . . . . 571

    Cholecystokinin (CCK) Test . . . . . 571

    Fecal Fat Analysis . . . . . 572

    Fecal Enzymes . . . . . 573

    Sweat Electrolyte Testing . . . . . 574

    Serum Enzymes . . . . . 574

    Tests of Gastric Secretion and Intestinal  
    Function . . . . . 575

**PART 5 Specialty Areas of  
Clinical Chemistry 579**

**CHAPTER 23 Body Fluid  
Analysis . . . . . 580**

*Kyle B. Riding*

Cerebrospinal Fluid . . . . . 581

Serous Fluids . . . . . 587

    Pleural Fluid . . . . . 588

    Pericardial Fluid . . . . . 589

    Peritoneal Fluid . . . . . 590

Amniotic Fluid . . . . . 591

    Hemolytic Disease of the Fetus and Newborn . . . . . 592

    Neural Tube Defects . . . . . 593

    Fetal Lung Maturity . . . . . 593

    Phosphatidylglycerol . . . . . 595

    Lamellar Body Counts . . . . . 595

Sweat . . . . . 596

Synovial Fluid . . . . . 597

**CHAPTER 24 Pregnancy  
and Prenatal Testing . . . . . 601**

*Heather L. Phillips and Michelle R. Campbell*

Pregnancy . . . . . 603

    Conception and Embryonic Development . . . . . 603

    Fetal Development . . . . . 603

    Delivery . . . . . 604

Transformation During Pregnancy . . . . . 604

    Plasma Volume Increase . . . . . 605

    Renin–Angiotensin–Aldosterone System . . . . . 605

    Natural Decreases in Analytes . . . . . 605

    Upregulation of Hormones and Steroids . . . . . 606

    Increased Glomerular Filtration Rate . . . . . 607

    Hyperventilation . . . . . 607

    Endocrine . . . . . 607

Cholesterols . . . . . 608  
 Immune System . . . . . 608  
 Neuroactive Hormones . . . . . 608

**Analytes for Maternal and Fetal Health Assessment. . . . . 608**

Human Chorionic Gonadotropin. . . . . 608  
 $\alpha$ -Fetoprotein (AFP) . . . . . 611  
 Fetal Amniotic Fluid  $\alpha$ -Fetoprotein. . . . . 612  
 Unconjugated Estriol. . . . . 612  
 Inhibin A. . . . . 613  
 The Triple and Quadruple Screen Test. . . . . 614  
 Acetylcholinesterase . . . . . 614  
 Pregnancy Associated Plasma Protein A (PAPP-A). . . . . 614  
 Progesterone . . . . . 614  
 Glucose . . . . . 615  
 Fetal Fibronectin. . . . . 615

**Common Diseases Associated with the Developing Fetus . . . . . 615**

Neural Tube Defects . . . . . 615  
 Down Syndrome . . . . . 616  
 Trisomy 18 . . . . . 617  
 Isoimmunization . . . . . 617  
 Preterm Delivery . . . . . 617

**Common Diseases Associated with the Mother and Pregnancy. . . . . 617**

Preeclampsia . . . . . 618  
 Hyperemesis Gravidarum . . . . . 618  
 Ectopic Pregnancy. . . . . 618  
 Analyte Deficiency. . . . . 619  
 Other Clinical Impairments. . . . . 619

**CHAPTER 25 Therapeutic Drug Monitoring . . . . . 622**

*Jie Gao and Floyd Josephat*

Pharmacokinetics . . . . . 624  
 Routes of Administration. . . . . 624  
 Drug Absorption. . . . . 624  
 Drug Distribution . . . . . 625  
 Free Versus Bound Drugs . . . . . 625  
 Drug Metabolism . . . . . 625  
 Drug Elimination . . . . . 626  
     Elimination Example . . . . . 628  
 Pharmacodynamics . . . . . 630  
 Specimen Collection . . . . . 631  
 Pharmacogenomics. . . . . 632  
 Cardioactive Drugs . . . . . 632  
     Digoxin . . . . . 632  
     Quinidine . . . . . 633

Procainamide and *N*-acetylprocainamide . . . . . 634  
 Disopyramide . . . . . 634

**Antibiotics. . . . . 635**

Aminoglycosides . . . . . 635  
 Gentamicin . . . . . 635  
 Tobramycin . . . . . 635  
 Amikacin. . . . . 635  
 Vancomycin. . . . . 636

**Antiepileptic Drugs . . . . . 636**

Primidone . . . . . 636  
 Phenobarbital . . . . . 636  
 Phenytoin and Free Phenytoin. . . . . 637  
 Valproic Acid . . . . . 637  
 Carbamazepine . . . . . 638  
 Ethosuximide . . . . . 638  
 Felbamate . . . . . 638  
 Gabapentin . . . . . 638  
 Lamotrigine. . . . . 639  
 Levetiracetam . . . . . 639  
 Oxcarbazepine . . . . . 639  
 Tiagabine. . . . . 640  
 Topiramate . . . . . 640  
 Zonisamide . . . . . 640

**Psychoactive Drugs . . . . . 640**

Lithium . . . . . 640  
 Tricyclic Antidepressants . . . . . 641  
 Clozapine . . . . . 641  
 Olanzapine . . . . . 641

**Immunosuppressive Drugs . . . . . 642**

Cyclosporine . . . . . 642  
 Tacrolimus. . . . . 642  
 Sirolimus. . . . . 642  
 Everolimus . . . . . 643  
 Mycophenolic Acid . . . . . 643

**Antineoplastics. . . . . 643**

Methotrexate . . . . . 643

**Bronchodilators . . . . . 644**

Theophylline . . . . . 644

**CHAPTER 26 Toxicology. . . . . 646**

*Christopher R. Swartz*

Xenobiotics, Poisons, and Toxins . . . . . 648  
 Routes of Exposure . . . . . 648  
 Dose–Response Relationship . . . . . 648  
     Acute and Chronic Toxicity . . . . . 649  
 Analysis of Toxic Agents . . . . . 650  
 Toxicology of Specific Agents . . . . . 651  
     Alcohols . . . . . 651  
     Carbon Monoxide . . . . . 654

Caustic Agents . . . . . 655  
 Cyanide . . . . . 655  
 Metals and Metalloids . . . . . 656  
 Pesticides . . . . . 660  
**Toxicology of Therapeutic Drugs . . . . . 661**  
     Salicylates . . . . . 661  
     Acetaminophen . . . . . 661  
**Toxicology of Drugs of Abuse . . . . . 662**  
     Amphetamines . . . . . 663  
     Sedatives–Hypnotics . . . . . 664  
     Barbiturates . . . . . 664  
     Benzodiazepines . . . . . 665  
     Cannabinoids: Tetrahydrocannabinol (THC) . . . . . 665  
     Cocaine . . . . . 665  
     Opioids . . . . . 665  
     Tricyclic Antidepressants . . . . . 666  
     Methylenedioxymethamphetamine . . . . . 666  
     Phencyclidine . . . . . 666  
     Anabolic Steroids . . . . . 667

**CHAPTER 27 Trace Elements, Toxic Elements, and Vitamins . . . . 669**

*Michelle R. Campbell*

**Trace and Toxic Elements . . . . . 670**  
     Instrumentation and Methods . . . . . 671  
     Aluminum . . . . . 676  
     Arsenic . . . . . 677  
     Cadmium . . . . . 678  
     Chromium . . . . . 679  
     Copper . . . . . 680  
     Iron . . . . . 681  
     Lead . . . . . 684  
     Manganese . . . . . 685  
     Mercury . . . . . 686  
     Molybdenum . . . . . 687  
     Selenium . . . . . 688  
     Zinc . . . . . 689  
**Vitamins . . . . . 690**  
     Overview . . . . . 690  
     Fat-Soluble Vitamins . . . . . 691  
     Water-Soluble Vitamins . . . . . 693

**CHAPTER 28 Tumor Markers . . . . . 703**

*Carleen Van Siclen*

**Types of Tumor Markers . . . . . 706**  
**Applications of Tumor Marker Detection . . . . 709**  
**Screening and Risk Assessment . . . . . 710**  
     Prognosis . . . . . 710  
     Monitoring Effectiveness of Therapy  
         and Disease Recurrence . . . . . 710

**Laboratory Considerations for  
 Tumor Marker Measurement . . . . . 710**  
     Immunoassays . . . . . 711  
     High-Performance Liquid Chromatography . . . . . 712  
     Immunohistochemistry  
         and Immunofluorescence . . . . . 712  
     Enzyme Assays . . . . . 712  
**Tumor Marker Tests . . . . . 713**  
      $\alpha$ -Fetoprotein . . . . . 713  
     Cancer Antigen 125 (CA-125) . . . . . 714  
     Carcinoembryonic Antigen (CEA) . . . . . 714  
     Human Chorionic Gonadotropin (hCG) . . . . . 716  
     Prostate-Specific Antigen (PSA) . . . . . 716  
     Cancer Antigen 15-3 (CA 15-3) . . . . . 719  
     Carbohydrate Antigen 19-9 (CA 19-9) . . . . . 719  
     Immunoglobulin Free Light Chains . . . . . 720  
     Human Epididymis Protein 4 (HE4) . . . . . 720  
     Neuron-Specific Enolase (NSE) . . . . . 721

**CHAPTER 29 Point-of-Care Testing . . . . . 724**

*Heather McNasby*

**Laboratory Regulations . . . . . 725**  
     Accreditation . . . . . 725  
     POCT Complexity . . . . . 725  
**Implementation . . . . . 727**  
     Establishing Need . . . . . 727  
     POCT Implementation Protocol . . . . . 727  
     Personnel Requirements . . . . . 728  
**Quality Management . . . . . 729**  
     Accuracy Requirements . . . . . 729  
     QC and Proficiency Testing . . . . . 729  
**POC Applications . . . . . 730**  
**Informatics and POCT . . . . . 732**

**CHAPTER 30 Newborn and Pediatric Clinical Chemistry . . . . . 734**

*Khushbu Patel and Tracey G. Polsky*

**Developmental Changes from  
 Neonate to Adult . . . . . 735**  
     Respiration and Circulation . . . . . 736  
     Growth . . . . . 736  
     Organ Development . . . . . 736  
     Problems of Prematurity  
         and Immaturity . . . . . 736  
**Pediatric Sample Collection  
 and Handling . . . . . 736**  
     Phlebotomy . . . . . 736  
     Preanalytic Concerns . . . . . 738  
     Choice of Analyzer . . . . . 738



Point-of-Care Analysis in Pediatrics ..... 738  
 Turnaround Time ..... 738  
 Evaluation of POCT Devices ..... 739  
 Device Limitations for Pediatric Use ..... 739  
 Regulation of Blood Gases and pH  
 in Neonates and Infants ..... 739  
 Blood Gas and Acid–Base Measurement ..... 740  
 Regulation of Electrolytes and Water:  
 Renal Function ..... 740  
 Disorders Affecting Electrolytes  
 and Water Balance ..... 741  
 Development of Liver Function ..... 742  
 Physiologic Jaundice ..... 742  
 Energy Metabolism ..... 742  
 Diabetes ..... 743  
 Nitrogen Metabolism ..... 744  
 Nitrogenous End Products as Markers  
 of Renal Function ..... 745  
 Liver Function Tests ..... 745  
 Calcium and Bone Metabolism  
 in Pediatrics ..... 746  
 Hypocalcemia and Hypercalcemia ..... 746  
 Endocrine Function in Pediatrics ..... 747  
 Hormone Secretion ..... 747  
 Hypothalamic–Pituitary–Thyroid System ..... 748  
 Hypothalamic–Pituitary–Adrenal  
 Cortex System ..... 748  
 Growth Factors ..... 749  
 Endocrine Control of Sexual Maturation ..... 750  
 Development of the Immune System ..... 750  
 Basic Concepts of Immunity ..... 750  
 Components of the Immune System ..... 750  
 Neonatal and Infant Antibody Production ..... 751  
 Immunity Disorders ..... 752  
 Genetic Diseases ..... 753  
 Cystic Fibrosis ..... 753  
 Newborn Screening for Whole  
 Populations ..... 754  
 Diagnosis of Metabolic Disease  
 in the Clinical Setting ..... 755  
 Drug Metabolism and  
 Pharmacokinetics ..... 757  
 Therapeutic Drug Monitoring ..... 757  
 Toxicologic Issues in Pediatric  
 Clinical Chemistry ..... 757

**CHAPTER 31 Geriatric Clinical  
 Chemistry ..... 760**

*Laura M. Hickes and J. Marvin McBride*

The Aging of America ..... 761  
 Aging and Medical Science ..... 762  
 General Physiologic Changes with Aging. . . . 765  
 Muscle ..... 765  
 Bone ..... 765  
 Gastrointestinal System ..... 765  
 Kidney/Urinary System ..... 765  
 Immune System ..... 766  
 Endocrine System ..... 766  
 Sex Hormones ..... 766  
 Glucose Metabolism ..... 767  
 Effects of Age on Laboratory Testing ..... 767  
 Muscle ..... 767  
 Bone ..... 767  
 Gastrointestinal System ..... 768  
 Urinary System ..... 768  
 Immune System ..... 769  
 Endocrine System ..... 769  
 Sex Hormones ..... 769  
 Glucose Metabolism ..... 769  
 Establishing Reference Ranges  
 for Older Adults ..... 769  
 Preanalytical Variables Unique  
 to Geriatric Patients ..... 770  
 Diseases Prevalent in Older Adults ..... 771  
 Age-Associated Changes  
 in Drug Metabolism ..... 773  
 Absorption ..... 774  
 Distribution ..... 774  
 Metabolism ..... 774  
 Elimination ..... 774  
 Atypical Presentations of Common  
 Diseases ..... 775  
 Geriatric Syndromes ..... 776  
 The Impact of Exercise and Nutrition  
 on Chemistry Results in the Geriatric  
 Population ..... 776  
**Appendix: Reference Ranges ..... 781**  
**Glossary ..... 789**  
**Index ..... 805**

To all Clinical Laboratory practitioners, educators, and healthcare professionals for their previous and continuing extraordinary commitment, service, and professionalism during the COVID-19 pandemic.

**MLB, EPF, CVS, JMM, MM**

---

In memory of my mother and father, Betty Beck Bishop and William Stewart Bishop, Sr., for support, guidance, and encouragement.

To Sheila, Chris, and Carson for their support, patience, and inspiration.

**MLB**

---

To Nancy, my wife, for continuing support and dedication.

**EPF**

---

To Gary, my husband, for his support of my professional goals and to all the laboratory professionals, including my students, who have contributed to my knowledge and passion for lifelong learning.

**CVS**

---

To my husband, Keith, for everything.

**JMM**

---

To my college mentors: Pete Gebauer and Herb Miller, I thank you for believing in me.

In memory of my mother SG (1940–2021)

**MM**

# Foreword

Many years ago, I wrote the Foreword to some earlier editions of this text. A ninth edition seems like an unbelievably long time until I reflect that this year is the 40<sup>th</sup> anniversary of the paper that introduced a multi-rule Shewhart control chart,<sup>1</sup> more commonly known as “Westgard Rules.” That paper was written early in my career, but now in my retirement we have updated that approach to provide “Westgard Sigma Rules” in order to customize the QC design on the basis of the quality required by a test and the Sigma performance observed for a method.<sup>2</sup> Even well-established “standard” laboratory practices need periodic review and updating to keep current with the improvements in testing processes. Likewise, this 9<sup>th</sup> edition of the standard clinical chemistry text reflects the latest knowledge and improvements for laboratory science. That is a testament to the authors’ commitment and dedication to providing an up-to-date knowledge base for the professionals in clinical laboratory science.

I am writing this on the one-year anniversary of the declaration of a global pandemic, a year during which over half a million Americans died of COVID-19. This pandemic has revealed the importance of laboratory testing for the health of the nation. Laboratory testing has often been viewed as a behind-the-scenes service in health care. During the pandemic, laboratory testing has been center stage as an essential service for assessing the state of disease, diagnosing those with infection, monitoring those under treatment, and monitoring the immunity and the health of the community.

Laboratory scientists were on the front line in introducing new diagnostic tests, validating their performance, and implementing testing in many diverse settings, including central laboratories, clinic laboratories, and point-of-care settings, including drive-through testing services. Understanding the performance of qualitative tests brought new importance to ideas such as clinical sensitivity, clinical specificity, and the predictive value of laboratory tests. That also meant new protocols for validating new tests to characterize test performance, including

adaptations for the nature of molecular tests, such as the real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) methods that were critical in the early diagnosis and management of patients. Antibody tests flooded the market and required care and attention by laboratories, especially during the early phases when the FDA exercised very limited control of the companies introducing the new tests. Antigen tests emerged later and more slowly but were critical for providing more widespread diagnostic testing. All in all, this short time period has provided the lessons of a lifetime and demonstrated the importance of what you will be learning in your studies.

This new edition of *Clinical Chemistry: Principles, Techniques, and Correlations* continues its mission of addressing the formal educational needs of students in clinical laboratory science, as well as the ongoing needs of professionals in the field. It facilitates the educational process by identifying the learning objectives, focusing on key concepts and ideas, and applying the theory through case studies. It covers the basics of laboratory testing, as well as many special areas of testing. And it is still possible to carry this text with you to class, to the laboratory, to the office, or home to study!

Having personally worked with some of the editors and contributors, I know they have high standards both in the laboratory and in the classroom. Their interests and background provide an excellent balance between the academic and the practical, ensuring that students are exposed to a well-developed base of knowledge that has been carefully refined by experience.

For the many students for whom this book is intended, let me offer some advice from my close friend and mentor, Hagar the Horrible. It seems his young Viking son was embarking on a voyage to the real world of work. Needing advice, he asked “How do I get to the top?” Hagar’s response, “You have to start at the bottom and work your way up.” After pondering this for a moment, his son then asked, “How do I get to the bottom?” Hagar replied, “You have to

know somebody.” The people you need to know are the authors of this book, as well as the instructors in your courses and your bench teachers in the laboratory. You need to seek them out to profit from their learning and experiences. They are the professionals who know the state of laboratory practice, possess the current knowledge of the field, and are dedicated to helping you become a successful laboratory scientist.

—James O. Westgard,  
Madison, WI

## References

1. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. *Clin Chem* 1981;27:493–501.
2. Westgard JO, Westgard SA. Establishing evidence-based statistical quality control practices. *Am J Clin Pathol* 2019;151:364–370.

# Preface

The events with the worldwide pandemic have placed an extraordinary burden on our healthcare system. Facing staffing, PPE, and diagnostic supply shortages, healthcare professionals stepped up with effort, critical process evaluation, and extraordinary dedication to provide quality patient care with compassion and empathy. Initially, the nightly news became a presentation of CDC guidelines, mask mandates, business shutdowns, travel restrictions, metrics, trends, positivity rates, and hospitalization and death statistics. Months later, the metrics related to more positive information—initial results of vaccine clinical trials, emergency use authorizations, vaccine shipments, and “shots in arms.” Through it all, the healthcare system functioned as effectively as possible due to individual efforts and interdisciplinary teamwork. Healthcare professionals have improved communication with each other, as well as with the patient and their families. Collaborative efforts between healthcare disciplines are emerging across the patient care spectrum landscape.

Since the initial idea for this textbook was discussed in a meeting of the Biochemistry/Urinalysis section of ASMT (now ASCLS) in the late 1970s, the only constant has been change and the never wavering commitment of the clinical laboratory professionals. Now almost 45 years since the initiation of this effort, the editors have had the privilege of completing the ninth edition with another diverse team of dedicated clinical laboratory professionals. In this era of focusing on metrics, the editors would like to share the following information. The 401 contributions in the 9 editions and supporting material represent 115 clinical laboratory science education programs, 83 clinical laboratories, 28 medical device companies, 4 government agencies, and 3 professional societies representing 40 states and territories. One hundred and sixty-four contributors were clinical laboratory scientists with advanced degrees. These contributors have produced 289 chapters citing 12,054 references for a total of 5,708 pages that included 2,158 figures and 691 case studies. With today's global focus, the previous editions of the text have been translated into

at least six languages. By definition, a profession is a calling requiring specialized knowledge and intensive academic preparation to define its scope of practice and produce its own literature. The clinical laboratory science profession has evolved significantly over these past four-and-a-half decades.

Clinical chemistry continues to be one of the most rapidly advancing areas of laboratory medicine. New technologies and analytical techniques have been introduced, with a dramatic impact on the practice of clinical chemistry and laboratory medicine. In addition, the healthcare system itself is rapidly changing. There is ever-increasing emphasis on improving the quality of patient care, individualized medicine, patient outcomes, financial responsibility, and total quality management. Now, more than ever, clinical laboratorians need to be concerned with disease correlations, result interpretations, problem solving, quality assurance, and cost-effectiveness. Laboratory professionals need to know not only the *how* of tests but more importantly be able to communicate the *what*, *why*, and *when* to the patient and the healthcare team. The editors of *Clinical Chemistry: Principles, Techniques, and Correlations* have designed the ninth edition to be an even more valuable resource to both students and practitioners.

The ninth edition of *Clinical Chemistry: Principles, Techniques, and Correlations* is comprehensive, up-to-date, and easy to understand for students at all entry levels. It is also intended to be a practically organized resource for both instructors and practitioners. The editors have tried to maintain the book's readability and further improve its content while rearranging content and focusing on the scaffolding provided by the ASCLS MLT and MLS Entry Level Curriculum and the ASCP BOC guidelines. Because clinical laboratorians use their interpretative and analytic skills in the practice of clinical chemistry, an effort has been made to maintain an appropriate balance between analytic principles, techniques, and the correlation of results with disease states.

In this edition, the editors have maintained features in response to requests from our readers,

students, instructors, and practitioners. Ancillary materials have been updated and expanded. Chapters now include current, more frequently encountered case studies modelled after the nursing PICOT initiative in a structured, unfolding style. To provide a thorough, up-to-date study of clinical chemistry, all chapters have been updated and reviewed by professionals who practice clinical chemistry and laboratory medicine on a daily basis. The basic principles of the analytic procedures discussed in the chapters reflect the most recent or commonly performed techniques in the clinical chemistry laboratory. Detailed procedures have been omitted because of the variety of equipment and commercial kits used in today's clinical laboratories. Instrument manuals and analyte package inserts are the most reliable reference for detailed instructions on current analytic procedures. All chapter material has been updated, improved, and rearranged for better continuity and readability.

The **Navigate 2 Advantage** digital access contains additional case studies, review questions, teaching resources, teaching tips, student laboratory procedures, and teaching aids for instructors and students; it is included with the purchase of this textbook and is also available for separate purchase from the publisher.

One last piece of advice to make you successful in the field of clinical laboratory science:

**Work with compassion, empathy, and professionalism until you no longer have to introduce yourself.\***

*Michael L. Bishop  
Edward P. Fody  
Carleen Van Siclen  
James March Mistler  
Michelle Moy*

\*Modified from Harvey Specter in *Suits*.



# New to This Edition

Medical laboratory science students need a strong foundation in applied chemistry to meet the requirements of certifying bodies and accreditation organizations that ensure students are prepared for employment.


This textbook provides clear explanations that balance analytic principles, techniques, and correlation of results with coverage of disease states, helping students develop interpretive and analytic skills for their future careers.

Updates to this edition include:

- Chapter content based on the ASCLS Entry Level Curriculum and current ASCP Content Guidelines

- Reorganization of chapter order to reflect clinical chemistry flow in most courses today
- Over 60 unique case studies that evolve throughout the chapters
- NEW Chapter 13: Basic Endocrinology
- NEW Chapter 24: Pregnancy and Prenatal Testing
- Reference range table is included as an Appendix in the printed book and online.

A map of how the textbook correlates to the ASCLS curriculum and ASCP guidelines is provided as an instructor resource.



**CHAPTER 9**

# Carbohydrates

Vicki S. Freeman

**CHAPTER OUTLINE**

**General Description of Carbohydrates**  
 Classification of Carbohydrates  
 Stereoisomers  
 Monosaccharides, Disaccharides, and Polysaccharides  
 Chemical Properties of Carbohydrates  
 Glucose Metabolism  
 Fate of Glucose  
 Regulation of Carbohydrate Metabolism

**Hyperglycemia**  
 Diabetes Mellitus  
 Pathophysiology of Diabetes Mellitus  
 Criteria for Testing for Prediabetes and Diabetes  
 Criteria for the Diagnosis of Diabetes Mellitus  
 Criteria for the Testing and Diagnosis of GDM

**Hypoglycemia**  
 Genetic Defects in Carbohydrate Metabolism  
**Role of the Laboratory in Differential Diagnosis and Management of Patients with Glucose Metabolic Alterations**  
 Methods of Glucose Measurement  
 Self-Monitoring of Blood Glucose  
 Glucose Tolerance and 2-Hour Postprandial Tests  
 Glycosylated Hemoglobin/HbA<sub>1c</sub>  
 Ketones  
 Albuminuria  
 Nitrit Autoantibody, Insulin Testing, and C-Peptide Testing

**References**

**KEY TERMS**

Albuminuria	Glycogen	Hg
Carbohydrates	Glycogenesis	Ht
Diabetes mellitus	Glycogenolysis	Ka
Disaccharides	Glycolysis	Mt
Embden-Meyerhof pathway	Glycosylated hemoglobin	Os
Glycogen	Hemoglobin A1c	Pt
Gluconeogenesis	Hyperglycemic	Tn
Glucose		

**CHAPTER OBJECTIVES**


At the end of this unit of study, the clinical laboratorian should be able to:

- Classify carbohydrates into their respective groups.
- Discuss the metabolism of carbohydrates in the body and the mode of action of hormones in carbohydrate metabolism.
- Differentiate the types of diabetes by clinical symptoms and laboratory findings according to the American Diabetes Association.
- Explain the clinical syndromes.
- Relate expected labor to the following metal:
  - Ketocetosis
  - Hyperosmolar coma
  - Distinguish between hypoglycemia.

**260**

Each chapter opens with a **Chapter Outline**, **Key Terms**, and **Chapter Objectives** that correlate to the ASCLS entry-level curriculum and current ASCP content guidelines.

**264 Chapter 9 Carbohydrates**



**Figure 9.6** Linkage of monosaccharides.

of sugars relies on the formation of glycosidic bonds that are bridges of oxygen atoms. When two carbohydrate molecules join, a water molecule is released. When they split, one molecule of water is consumed to form the individual sugar compounds. This reaction is called hydrolysis. The glycosidic linkages of carbohydrate can involve any number of carbons; however, certain carbons are favored, depending on the carbohydrate. **Monosaccharides** are simple sugars that cannot be hydrolyzed to a simpler form; there is one sugar molecule. These sugars can contain three, four, five, or six or more carbon atoms (known as trioses, tetroses, pentoses, and hexoses, respectively). The most common hexose monosaccharides include glucose, fructose, and galactose.

**Disaccharides** are formed when two monosaccharide units are joined by a glycosidic linkage. On hydrolysis, disaccharides will be split into two monosaccharides by disaccharidase (enzyme located on the microvilli of the enteric monosaccharides are then actively absorbed). The most common disaccharides are maltose (two d-glucose molecules in a 1 → 4 linkage) and sucrose.

**Oligosaccharides** are the chains of 10 sugar units, whereas **polysaccharides** are the linkage of many monosaccharide hydrolysis, polysaccharides will yield 10 monosaccharides. Amylase, an enzyme found in the stomach, hydrolyzes starch to dextrin in the duodenum. The most common polysaccharide is starch (plant based glucose molecule) and glycogen (animal based glucose molecules).

**Chemical Properties of Carbohydrates**

Some carbohydrates are reducing substances. Carbohydrates can reduce other compounds; they themselves are oxidized. To be a reducing substance, the carbohydrate must contain (available) ketone or an aldehyde group. Fehling's test was used in many past laboratories to determine the determination of carbohydrates.

Carbohydrates can form glycosidic bonds with other carbohydrates and with noncarbohydrates. Two sugar molecules can be joined in tandem, forming a glycosidic bond between the hemiacetal group of one molecule and the hydroxyl group on the other molecule. In forming the glycosidic bond, an acetal is generated on one sugar (at carbon 1) in place of the hemiacetal. If the bond forms with one of the other carbons on the carbohydrate other than the anomeric (reducing) carbon, the anomeric carbon is unaffected, and the resulting compound remains a reducing substance. Examples of common-reducing sugars include glucose, maltose, fructose, lactose, and galactose. If a glycosidic bond is formed with the anomeric carbon on the other carbohydrate, the resulting compound is no longer a reducing substance. Nonreducing carbohydrates do not have an active ketone or aldehyde group and therefore will not reduce other

Key Terms are also highlighted within the chapter and defined in the book's Glossary.



# Glossary

**1,25-Dihydroxyvitamin D ([OH]<sub>2</sub>D) (calcitriol)** Active metabolite of vitamin D; induces active absorption of calcium in the small intestine.

**1<sub>α</sub>-rule** A data quality control rule that indicates that one data point cannot exceed three SDs. The presence of a data point beyond 3 SDs would trigger a rejection of the analytic run.

**25-Hydroxyvitamin D** Inactive precursor of 1,25-dihydroxyvitamin D.

**5-Dihydrotestosterone (DHT)** An androgenic androgen sex steroid and hormone. The enzyme 5α-reductase catalyzes the formation of DHT from testosterone in certain tissues including the prostate gland, seminal vesicles, epididymides, skin, hair follicles, liver, and brain.

**A**

**Accuracy** How close the measured value is to the true value due to systematic error, which can be either constant or proportional.

**Acidemia** A condition in which the pH of blood is below the lower limit of the reference range (<7.35), indicating that the hydrogen-ion concentration in the blood is increased.

**Activation energy** The excess energy needed to form the transition state of a reaction.

**Activators** Inorganic cofactors, such as metal ions, needed for enzyme activity.

**Active transport** Use of energy to move ions or substances across cell membranes.

**Acute coronary syndrome (ACS)** A progression of pathologic conditions involved in subacute heart disease, including erosion and rupture of coronary artery plaques, activation of platelets, and thrombosis. This progression ranges from unstable angina to extensive tissue necrosis in acute myocardial infarction.

**Acute kidney injury (AKI)** A sudden, sharp decline in renal function as a result of an acute toxic or hypoxic insult to the kidneys.

**Adrenocorticotropic hormone (ACTH)** A peptide hormone secreted by the anterior pituitary. It stimulates the cortex of the adrenal glands to produce adrenal cortical hormones.

**Affinity** Attraction or force causing two substances to unite.

**Arboreal pathogens** Any infectious agent transmissible by air, e.g., tuberculosis, virus particle, etc.

**Albuminuria** The presence of albumin in the urine.

**Albosteron** The main mineralocorticoid steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. This hormone controls the sodium-potassium pump, the primary mechanism for sodium reabsorption in the kidney and regulator of the blood sodium and potassium levels.

**Alkalemia** A condition in which blood pH is greater than the uppermost limit of the reference range (>7.45), indicating that the hydrogen ion concentration in the blood is decreased.

**Amniocentesis** Empirical cessation of menstruation in a female who is past menarche but not yet in menopause.

**Amino acids** Hormones that are derived directly from amino acids.

**Amino acid** Simple organic compounds that serve as the building blocks of proteins; contain at least one amine functional group, one carbonyl function group, and a unique R group.

**Aminoacidopathies** Inborn errors of metabolism that inhibit the body's ability to metabolize specific amino acids.

**Ammonia** A compound consisting of nitrogen and hydrogen. Formula: NH<sub>3</sub> or H<sub>3</sub>N.

**Amniocentesis** Procedure of the amniotic sac to obtain fluid for analysis.

**Amniotic fluid (AF)** A fluid in which the fetus is suspended; it provides a cushioning medium for the fetus and serves as a matrix for reflex and efflux of constituents.

**Ampereometry** The measurement of amperes. It is the unit of measure for electric current. The reduction of oxygen produces a current that is proportional to the amount of oxygen present in the sample.

**Amphiprotic** A molecule that is both an acid and a base.

**Analyte** Substance of interest being measured.

**Analytic** Introduced during the phase of processing and assaying the specimen in the clinical laboratory.

**Analytic measurement range (AMR)** Also known as linear or dynamic range. Range of analyte concentrations that can be directly measured without dilution, concentration, or other pretreatment.

**781**



**Case Studies** with patient visuals progress through the chapter and pose critical-thinking questions, prompting students to synthesize and apply their new knowledge. A case study answer key is available to instructors.

**CASE STUDY 4.1, PART 1**

Remember Miles and Mia from Chapter 1? The laboratory is placing a spectrophotometer back in service after being in storage for 6 months. The instrument manuals are no longer available for this model. Miles and Mia, who manage quality control for the laboratory, are tasked with getting it ready for use.

1. What procedures should Miles and Mia develop to validate that the instrument is working properly for clinical use?



© Andrew Duchonnet



© Sam Sutter/Topical Images/Getty Images

**CASE STUDY 6.2, PART 1**

Guillermo, a 47-year-old man, had fallen and broken his leg. In the emergency department, he explained his complicated medical history with type 2 diabetes, peripheral neuropathy, and chronic renal insufficiency. His complete blood count (CBC) showed a normochromic, normocytic anemia.



© Ronald Pineda/Topical Images/Getty Images

**CASE STUDY 6.2, PART 2**

Remember Guillermo, the 47-year-old man who had fallen and broken his leg. The radiograph of his ankle showed bone loss. Based on admitting chemistry test results, the provider ordered a serum protein electrophoresis.

1. Compare the image of the electrophoresis gel (Figure A) to the reference pattern in Figure 6.9. What protein fraction shows an increase?
2. What additional test should be ordered to identify the increased protein?



Red with permission from Hahn's Laboratory




© Ronald Pineda/Topical Images/Getty Images

**CASE STUDY 6.2, PART 3**

Remember Guillermo, the 47-year-old man who had fallen and broken his leg.

3. Compare the image of Guillermo's electropherogram from the densitometer (Figure B) to the reference patterns in Figure 6.10. Which pattern looks the most similar?



Red with permission from Hahn's Laboratory



© Ronald Pineda/Topical Images/Getty Images


**CASE STUDY 6.2, PART 4**

Remember Guillermo, the 47-year-old man who had fallen and broken his leg. His provider ordered an IFE and the results are now available.

4. Evaluate the image of Guillermo's serum immunofixation electrophoresis in Figure C. Figure A is the serum protein electrophoresis (SPE). If you turn Figure C 90° to the right, it will look like the SPE pattern in Figure A. What immunoglobulin heavy chain is prominent? What light chain is in the same location and has similar staining intensity?
5. How would this gammopathy be classified?




© Ronald Pineda/Topical Images/Getty Images



A

B

C



Units of Measure **5**

**SI CONVERSIONS**

To convert between SI units, move the decimal the difference between the exponents represented by the prefix of the base unit. When moving from a larger unit to a smaller unit, the decimal will move to the right. When converting from a smaller unit to a larger unit, the decimal will move to the left.

If converting from smaller unit to larger unit, then move decimal to the left the exponent difference.

If converting from larger unit to smaller unit, then move decimal to the right the exponent difference.

point moves to the left three places to become 1.0 L. Note that the SI term for mass is kilogram, which is the only basic unit that contains a prefix as part of its name. Generally, the clinical laboratory uses the term gram for mass rather than kilogram.

**Example 1: Convert 1.0 L to  $\mu\text{L}$ .**

1.0 L ( $1 \times 10^0$ )  
 $\mu\text{L}$  (micro =  $10^{-6}$ )

The difference between the exponents = 6. The conversion is from a larger unit to a smaller unit, so the decimal will move 6 places to the right.

1.0 L = 1,000,000  $\mu\text{L}$ .

**Example 2: Convert 5 mL to  $\mu\text{L}$ .**

5 mL (milli =  $10^{-3}$ )  
 $\mu\text{L}$  (micro =  $10^{-6}$ )

The difference between the exponents = 3. The conversion is from a larger unit to a smaller unit, so the decimal will move 3 places to the right.

5 mL = 5000  $\mu\text{L}$ .

**Table 1.2 Prefixes Used with SI Units**

Factor	Prefix	Symbol
$10^{-9}$	atto	a
$10^{-15}$	femto	f
$10^{-12}$	pic	p
$10^{-9}$	nano	n
$10^{-6}$	micro	$\mu$
$10^{-3}$	milli	m
$10^{-1}$	centi	c
$10^{-2}$	deci	d
$10^0$	Liter, meter, gram	l, m, g
$10^1$	deka	da
$10^2$	hecto	h
$10^3$	kilo	k
$10^6$	mega	M
$10^9$	giga	G
$10^{12}$	tera	T
$10^{15}$	peta	P
$10^{18}$	exa	E

Prefixes are used to indicate a value is a multiple of a basic SI unit.  
 © Jones & Bartlett Learning.

**Boxes** emphasize important points and additional information.

**Examples** highlight important formulas and how to use them in a convenient, numbered format.

**Equations** are presented throughout in a conveniently numbered format.

20 Chapter 1 Basic Principles and Practices of Clinical Chemistry

### Laboratory Mathematics and Calculations

**Significant Figures**

**Significant figures** are the minimum number of digits needed to express a particular value in scientific notation without loss of accuracy. There are several rules in regard to identifying significant figures:

- All nonzero numbers are significant (1, 2, 3, 4, 5, 6, 7, 8, 9).
- All zeros between nonzero numbers are significant.
- All zeros to the right of the decimal are not significant when followed by a nonzero number.
- All zeros to the left of the decimal are not significant.

The number 814.2 has four significant figures, because in scientific notation, it is written as  $8.142 \times 10^2$ . The number 0.000641 has three significant figures, because the scientific notation expression for this value is  $6.41 \times 10^{-4}$ . The zeros to the right of the decimal preceding the nonzero digits are merely holding decimal places and are not needed to properly express the number in scientific notation. However, by convention, zeros following a decimal point are considered significant. For example, 10.00 has four significant figures. The zeros to the right of the decimal indicate the precision of this value.

**Logarithms**

Logarithms are the inverse of exponential functions and can be related as such:

$$x = A^B \text{ or } B = \log_x(A)$$

This is then read as B is the log base A of X, where B must be a positive number, A is a positive number, and A cannot be equal to 1. Calculators with a log function do not require conversion to scientific notation.

To determine the original number from a log value, the process is performed in reverse. This process is termed the *antilogarithm* or *antilog* as it is the inverse of the logarithm. Most calculations require using an inverse or secondary shift function when entering this value. If given a log of 3.1525, the resulting value is  $1.424 \times 10^3$  on the base 10 system. Consult the specific manufacturer's directions of the calculator to become acquainted with the proper use of these functions.

**pH (Negative Logarithms)**

In certain circumstances, the laboratory may work with negative logs. Such is the case with pH or  $pK_a$ . As previously stated, the pH of a solution is defined as the negative log of the hydrogen ion concentration. The following is a convenient formula to determine the negative logarithm when working with pH or  $pK_a$ :

$$\frac{\text{pH}}{\text{pK}_a} = x - \log N \quad (\text{Eq. 1.11})$$

where x is the negative exponent base 10 expressed and N is the decimal portion of the scientific notation expression.

For example, if the hydrogen ion concentration of a solution is  $5.4 \times 10^{-6}$ , then  $x = 6$  and  $N = 5.4$ . Substitute this information into Equation 1.11, and it becomes

$$\text{pH} = 6 - \log 5.4 \quad (\text{Eq. 1.12})$$

The logarithm of N (5.4) is equal to 0.7324, or 0.73. The pH becomes

$$\text{pH} = 6 - 0.73 = 5.27 \quad (\text{Eq. 1.13})$$

The same formula can be applied to obtain the hydrogen ion concentration of a solution when only the pH is given. Using a pH of 5.27, the equation becomes

$$5.27 = x - \log N \quad (\text{Eq. 1.14})$$

In this instance, the x term is always the next largest whole number. For this example, the next largest whole number is 6. Substituting for x, the equation becomes

$$5.27 = 6 - \log N \quad (\text{Eq. 1.15})$$

A shortcut is to simply subtract the pH from x ( $6 - 5.27 = 0.73$ ) and take the antilog of that answer 5.73. The final answer is  $5.73 \times 10^{-6}$ . Note that rounding, while allowed, can alter the answer. A more algebraically correct approach follows in Equations 1.16 through 1.18. Multiply all the variables by -1:

$$(-1)(5.27) = (-1)(6) - (-1)(\log N) \quad (\text{Eq. 1.16})$$

$$-5.27 = -6 + \log N$$

**Table 5.4** Competitive Binding Assay Example

AD	+	AD*	+	AB	->	ADAB	+	AD*AB	+	AD*
CONCENTRATION OF REACTANTS					CONCENTRATION OF PRODUCTS					
AD		AD*		AB		ADAB		AD*AB		AD*
0		200		100		0		100		100
50		200		100		20		80		120
100		200		100		34		66		134
200		200		100		50		50		150
400		200		100		66		34		166

**SAMPLE CALCULATIONS**

Dose of [Ag]	% B	B/F
0	$\frac{100}{200} = 50$	$\frac{100}{100} = 1$
50	$\frac{80}{200} = 40$	$\frac{80}{120} = 67$
100	$\frac{66}{200} = 33$	$\frac{66}{134} = 39$
200	$\frac{50}{200} = 25$	$\frac{50}{150} = 33$
400	$\frac{34}{200} = 17$	$\frac{34}{166} = 20$

AD, unlabeled antigen; AD\*, labeled antigen; AB, antibody; ADAB, antigen-antibody complex; AD\*, labeled and © Jones & Bartlett Learning

equally to the Ab. As the concentration of Ag increases in a competitive assay, the amount of tracer that complexes with the binding reagent decreases. If the tracer is of low molecular weight, free tracer is often measured. If the tracer is of high molecular weight, the bound tracer is measured. The data may be plotted in one of three ways: bound/free versus the arithmetic dose of unlabeled Ag, percentage bound versus the log dose of unlabeled Ag, and log bound/free versus the log dose of the unlabeled Ag (Figure 5.11).

The bound fraction can be expressed in several different formats. Bound/free is counts per minute (CPM) of the bound fraction compared with the CPM of the free fraction. Percent bound (% B) is the CPM of the bound fraction compared with the CPM of maximum binding of the tracer (B<sub>0</sub>) multiplied by 100. Log<sub>10</sub> B/F transformation is the natural log of (B/F)<sub>0</sub> (1 - B/B<sub>0</sub>). When B/F<sub>0</sub> is plotted

on Ag, the log of the bound fraction is plotted on the y-axis.

Figures and Tables provide dynamic visuals and populate the new edition throughout, including illustrations, photos, charts, and graphs.


**Table 21.1** Kidney Functions

Urine formation
Fluid and electrolyte balance
Regulation of acid-base balance
Excretion of the waste products of protein metabolism
Excretion of drugs and toxins
Secretion of hormones
Renin
Erythropoietin
1,25-Dihydroxyvitamin D <sub>3</sub>
Prostaglandins



the body by way of the urethra. The highlighted section in Figure 21.1 shows the arrangement of **nephrons** in the kidney; nephrons are functional

units of the kidney that can only be seen microscopically. Each kidney contains approximately 1 million nephrons. Each nephron is a complex apparatus composed of five basic parts as shown in Figure 21.2.

- These five parts are:
- The **glomerulus**—a capillary tuft surrounded by the expanded end of a renal **tubule** known as Bowman's capsule. Each glomerulus has an afferent arteriole that carries the blood in and an efferent arteriole carrying the blood out. The efferent arteriole branches into peritubular capillaries that supply the tubule.
  - The proximal convoluted tubule—located in the cortex.
  - The long loop of Henle—composed of the thin descending limb, which spans the medulla, and the ascending limb, which is located in both the medulla and the cortex, composed of a region that is thin and then thick.
  - The distal convoluted tubule—located in the cortex.




**Figure 21.1** Anatomy of the kidney



**Figure 3.14** (A) Histogram of total thyroxine (T<sub>4</sub>) levels in a real population illustrating a shape indicative of a Gaussian distribution, which is analyzed by parametric statistics. The reference range is determined from the mean  $\pm$  1.96 SDs. (B) Histogram of  $\beta$ -human chorionic gonadotropin (hCG) levels in a population of pregnant women demonstrating non-Gaussian data and nonparametric determination of the reference range. The reference range is determined from percentiles to include the central 95% of values, although the selection of a wide range of gestational ages makes this a poor population for a reference range study, it does demonstrate the application of nonparametric intervals.

## Student Resources



To support your learning, review the chapter learning objectives and complete the online activities. The **Navigate 2 Advantage Access** included with each new print copy of this book offers a wealth of resources. These include practical learning activities and study tools such as flashcards, math practice, an eBook with interactive questions, and more!

- eBook with embedded assessments
- Case Studies

- Review Questions
- Flashcards
- Reference Range Table
- General Reference Tables
- Supplemental Chapter
  - Molecular Theory and Techniques

## Instructor Resources

Instructor resources, available to qualified instructors, include the following:

- Learning Objectives mapped to:
  - ASCLS Entry-Level Curriculum (MLS and MLT)
  - Current ASCP Board of Certification Content Guidelines (MLS and MLT)
- Slides in PowerPoint format
- Teaching Resources
- Test Bank (Available in LMS-compatible formats)
- Student Lab Procedures
- Image Bank
- Answer Key to Case Studies
- Answer Key to Eighth Edition Case Studies
- Answer Key to Review Questions
- Sample Syllabus

# Acknowledgments

A project as large as this requires the assistance and support of many clinical laboratorians. The editors wish to express their appreciation to the contributors of all the editions of *Clinical Chemistry: Principles, Techniques, and Correlations*—the dedicated laboratory professionals and educators whom the editors have had the privilege of knowing and exchanging ideas with over the years. These individuals were selected because of their expertise in particular areas and their commitment to the education of clinical laboratorians. Many have spent their professional careers in the clinical laboratory, at the bench, teaching students, or consulting with clinicians. In these frontline positions, they have developed a perspective of what is important for the next generation of clinical laboratorians.

We extend appreciation to our students, colleagues, teachers, and mentors in the profession who have helped shape our ideas about clinical chemistry practice and education. Also, we want to thank the

many companies and professional organizations that provided product information and photographs or granted permission to reproduce diagrams and tables from their publications. The ASCLS Entry Level Curriculum and CLSI documents have also been important sources of information. These documents are directly referenced in the appropriate chapters.

The editors would like to acknowledge the contribution and effort of all individuals to previous editions. Their efforts provided the framework for many of the current chapters. Finally, we gratefully acknowledge the cooperation and assistance of the staff at Jones & Bartlett Learning for their advice and support.

The editors are continually striving to improve future editions of this book. We again request and welcome our readers' comments, criticisms, and ideas for improvement.

**MLB, EPF, CVS, JMM, MM**

# Contributors

**Karen K. Apolloni, MSA, MLS(ASCP)<sup>CM</sup>**

Director (Academic), Clinical Laboratory Science Program  
Wayne State University  
Detroit, Michigan

**Nikola A. Baumann, PhD, DABCC**

Co-Director of Central Clinical Laboratory and Central Processing  
Department of Laboratory Medicine and Pathology  
Mayo Clinic  
Rochester, Minnesota

**Heather McNasby, MT(ASCP), MSHS**

Manager of Clinical Laboratory Services  
Nemours Children's Hospital  
Orlando, Florida

**Takara L. Blamires, MS, MLS(ASCP)<sup>CM</sup>**

Associate Professor, MLS Undergraduate Program  
Director  
Department of Pathology  
University of Utah School of Medicine  
Salt Lake City, Utah

**Michelle R. Campbell, MS, MLS(ASCP)<sup>CM</sup>MBC<sup>CM</sup>**

Development Technologist  
Department of Laboratory Medicine and Pathology  
Mayo Clinic  
Rochester, Minnesota  
Adjunct Instructor  
Department of Allied Health Sciences, Division of Clinical Laboratory Science  
University of North Carolina School of Medicine  
Chapel Hill, North Carolina

**Janelle M. Chiasera**

Dean and Professor  
School of Health Sciences  
Quinnipiac University  
Hamden, Connecticut

**Kathryn Dugan, MEd, MT(ASCP)**

Assistant Professor  
Medical and Clinical Laboratory Sciences  
Auburn University at Montgomery  
Montgomery, Alabama

**Vicki S. Freeman, PhD, MASCP, MLS(ASCP)<sup>CM</sup>SC<sup>CM</sup>, FAACC**

Professor  
Clinical Laboratory Sciences  
Associate Dean for Faculty Development  
School of Health Professions  
University of Texas Medical Branch  
Galveston, Texas

**Jie Gao, PhD, MLS(ASCP)<sup>CM</sup>**

Assistant Professor  
Department of Clinical and Diagnostic Science  
University of Alabama at Birmingham  
Birmingham, Alabama

**Brandy Greenhill, DrPH, MLS(ASCP)<sup>CM</sup>**

Professor  
University of Texas MD Anderson School of Health Professions  
Houston, Texas

**Matthew P.A. Henderson, PhD, FCACB, FCCMG**

Laboratory Head of Biochemistry  
Newborn Screening Ontario  
Assistant Professor  
Department of Pediatrics  
Children's Hospital of Eastern Ontario, University of Ottawa  
Ottawa, Ontario  
CANADA

**Laura M. Hickes**

Chemistry and Applications Support Manager  
Roche Diagnostics  
Indianapolis, Indiana

**Kristina Jackson Behan, PhD, MLS(ASCP)**

Professor  
Medical Laboratory Sciences  
University of West Florida  
Pensacola, Florida

**Stephanie L. Jacobson, MS, MLS(ASCP)<sup>CM</sup>**

MLS Online Instructor  
Allied and Population Health  
Medical Laboratory Scientist  
Monument Health  
Rapid City, South Dakota  
South Dakota State University  
Brookings, South Dakota

**Floyd Josephat, EdD, MT(ASCP)**

Professor and Program Director  
Clinical and Diagnostic Sciences  
Graduate Faculty II  
University of Alabama at Birmingham  
Birmingham, Alabama

**Brooke M. Katzman, PhD**

Co-Director of Hospital Clinical Laboratory and  
Point of Care  
Department of Laboratory Medicine and Pathology  
Mayo Clinic  
Rochester, Minnesota

**Kathleen M. Kenwright, EdD, MLS(ASCP)<sup>CM</sup>, MB**

Medical Laboratory Science Program Director  
Diagnostic and Health Sciences  
Associate Professor  
University of Tennessee Health Science Center  
Memphis, Tennessee

**John E. Lee Sang, MD**

Laboratory Director Clinical Pathology Associates  
Pathology Department  
San Marcos, Texas  
Clinical Pathology Associates  
San Marcos, Texas

**Cyndy B. Levtzow, BS, MT(ASCP), LSSBB**

Retired; Previous Clinical Core Supervisor and  
Assistant Administrative Director  
Formerly UNC Hospitals, McLendon Clinical  
Laboratories  
Chapel Hill, North Carolina

**Shawn H.W. Luby, MS, MLS(ASCP)<sup>CM</sup>**

Assistant Professor  
Division of Clinical Laboratory Science  
University of North Carolina School of Medicine  
Chapel Hill, North Carolina

**James March Mistler, ABD, MS, MLS(ASCP)<sup>CM</sup>**

Program Director and Fulltime Lecturer  
Department of Medical Laboratory Science  
University of Massachusetts Dartmouth  
North Dartmouth, Massachusetts

**J. Marvin McBride, MD, MBA**

Clinical Assistant Professor  
Department of Medicine  
University of North Carolina at Chapel Hill School of  
Medicine  
Chapel Hill, North Carolina

**Christopher R. McCudden, PhD, FACB, FCACB**

Clinical Biochemist  
Division of Biochemistry  
Associate Professor  
Department of Pathology & Laboratory Medicine  
The Ottawa Hospital, University of Ottawa  
Ottawa, Ontario  
CANADA

**Scott Moore, DO, MLS(ASCP)<sup>CM</sup>, DipIBLM**

Assistant Professor of Medical Laboratory Sciences  
Department of Medical Laboratory Sciences  
Weber State University  
Ogden, Utah

**Teresa A. Mortier, PhD, MT(ASCP)**

Assistant Professor  
School of Health Sciences  
Eastern Michigan University  
Ypsilanti, Michigan

**Yukari Nishizawa-Brennen, PhD, MLS(ASCP)<sup>CM</sup>,  
MT(Japan)**

Assistant Professor  
Biomedical Laboratory Diagnostics Program  
Michigan State University  
East Lansing, Michigan

**Peter P. O'Brien, MBA, MT(ASCP)**

Program Director Medical Laboratory Technician  
Program  
Allied Health Sciences  
Jackson State Community College  
Jackson, Tennessee

**Khushbu Patel, PhD, DABCC**

Director of Clinical Chemistry and Point-of-Care  
Children's Hospital of Philadelphia Department of  
Pathology and Laboratory Medicine  
Assistant Professor of Pathology and Laboratory  
Medicine  
Perelman School of Medicine  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Heather L. Phillips, PhD, MLS(ASCP)<sup>CM</sup>, MT(AMT)**

Director Austin Peay State University COVID-19  
Testing Laboratory  
COVID-19 Molecular Laboratory  
Assistant Professor  
Allied Health Sciences—Medical Laboratory Sciences  
Austin Peay State University  
Clarksville, Tennessee

**Tracey G. Polsky, MD, PhD**

Chief, Division of Community Pathology  
Children's Hospital of Philadelphia Department of  
Pathology and Laboratory Medicine  
Assistant Professor of Pathology and Laboratory  
Medicine  
Perelman School of Medicine  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Gerald D. Redwine, PhD, MT(ASCP)**

Associate Professor  
Clinical Laboratory Science Program  
Texas State University  
San Marcos, Texas

**Kyle B. Riding, PhD, MLS(ASCP)<sup>CM</sup>**

Assistant Professor of Medicine  
Burnett School of Biomedical Science, College of  
Medicine  
University of Central Florida  
Orlando, Florida

**Amanda Rivera-Begeman, DO**

Pathologist, Chief of Pathology Medical Education  
Pathology Department  
Clinical Pathology Associates  
Dell Medical School at the University of Texas at  
Austin  
Austin, Texas

**Michael W. Rogers, MBA, MT(ASCP)**

Laboratory Technical Consultant  
Public Health Laboratory  
Independent Contractor  
Winston Salem, North Carolina

**Jane R. Semler, MS, MT(ASCP)**

Professor  
Allied Health Sciences  
Coordinator, MLT to MLS Program  
Austin Peay State University  
Clarksville, Tennessee

**Rebecca D. Silva, MS, MT(ASCP)**

Department Chair, Assistant Professor  
Medical Laboratory Technology Program  
New England Institute of Technology  
East Greenwich, Rhode Island

**Donna J. Spannaus-Martin, PhD, MLS(ASCP)<sup>CM</sup>**

Professor, Medical Laboratory Sciences Program  
University of Minnesota  
Minneapolis, Minnesota

**Christopher Swartz, PhD, MLS(ASCP)**

Assistant Professor  
Department of Health and Clinical Sciences  
University of Kentucky, College of Health Sciences  
Lexington, Kentucky

**Yun L. Trull, PhD, DABCC**

Director of Clinical Chemistry  
Pathology and Laboratory Medicine  
Allegheny Health Network  
Pittsburgh, Pennsylvania

**Carleen Van Siclen, MS, MLS(ASCP)<sup>CM</sup>, TS(ABB)**

Assistant Professor of Laboratory Medicine and  
Pathology  
MCSHS Medical Laboratory Science Program  
Mayo Clinic  
Jacksonville, Florida

**Elizabeth Warning, MS, MLS(ASCP)<sup>CM</sup>, AHI (AMT)**

Associate Professor, Educator  
Clinical & Health Information Sciences  
Program Director, MLS Campus Based Program  
College of Allied Health Sciences  
University of Cincinnati  
Cincinnati, Ohio

**Monte S. Willis, MD, PhD, MBA, FASCP, FCAP, FAHA**

Medical Director, Clinical Pathology, Allegheny  
Health Network, Allegheny General Hospital  
Core Laboratory  
Pathology and Laboratory Medicine  
Patient Experience Officer, Pathology Institute  
Allegheny Health Network  
Pittsburgh, Pennsylvania



# Ancillary Contributors

**Brenda C. Barnes, PhD, MT(ASCP)SBB**

Director, Medical Laboratory Science Program  
Professor  
Allen College  
Waterloo, Iowa

**Leigh A. Belair, MEd, MT(ASCP)**

Program Director, MLT Program of Maine  
Associate Professor  
University of Maine at Presque Isle  
Presque Isle, Maine

**Michael L. Bishop, MS, MLS(ASCP)**

Adjunct Faculty, Medical Laboratory Scientist  
Program  
Santa Fe College  
Alachua, Florida  
Retired Faculty, Medical Technology Program  
Duke University Medical Center  
Durham, North Carolina  
Retired Program Director and University Department  
Chair, Medical Laboratory Science and Medical  
Laboratory Technician Program  
Keiser University  
Orlando, Florida

**Jie Gao, PhD, MLS(ASCP)<sup>CM</sup>**

Assistant Professor  
Department of Clinical and Diagnostic Science  
University of Alabama at Birmingham  
Birmingham, Alabama

**James March Mistler, ABD, MS, MLS(ASCP)<sup>CM</sup>**

Program Director and Fulltime Lecturer  
Department of Medical Laboratory Science  
University of Massachusetts Dartmouth  
North Dartmouth, Massachusetts

**Michelle Moy, MAdEd, MT(ASCP) SC**

Assistant Professor of Medical Laboratory Science  
Program Director, Biomedical Science  
Department of Natural Science and Mathematics,  
College of Arts and Sciences  
Madonna University  
Livonia, Michigan

**Carmen Pierce, MS CLS (ASCP)<sup>CM</sup>**

Full Time Lecturer  
University of Massachusetts Dartmouth  
Dartmouth, Massachusetts

**Carleen Van Siclen, MS, MLS(ASCP)<sup>CM</sup>, TS(ABB)**

Faculty, MCSHS Medical Laboratory Science Program  
Assistant Professor, Mayo Clinic College of Medicine,  
Department of Laboratory Medicine and Pathology  
Mayo Clinic  
Jacksonville, Florida



# Reviewers

**Laurie B. Alloway, MSES, MLS(ASCP)<sup>CM</sup>, SC(ASCP)<sup>CM</sup>, EMT**

Associate Teaching Professor  
Medical Laboratory Sciences Dept.  
Wichita State University  
Wichita, Kansas

**Nancy D. Cruz-Sanchez, MS, MLS(ASCP)<sup>CM</sup>**

Lecturer  
Clinical Laboratory Science Program  
The University of Texas at El Paso  
El Paso, Texas

**Lorraine Doucette, MS, MLS(ASCP)<sup>CM</sup>**

Assistant Professor, MLS Program Director  
Department of Medical and Research Technology  
University of Maryland School of Medicine  
Baltimore, MD

**Jie Gao, PhD, MLS(ASCP)<sup>CM</sup>**

Assistant Professor  
Department of Clinical and Diagnostic Science  
University of Alabama at Birmingham  
Birmingham, Alabama

**Daniela Gill, MSHS, MLS(ASCP)<sup>CM</sup>**

Clinical Assistant Professor  
University of Texas Rio Grande Valley  
Edinburg, Texas



# Basic Principles and Practice in Clinical Chemistry

CHAPTER 1	Basic Principles and Practices of Clinical Chemistry . . . . .	2
CHAPTER 2	Laboratory Safety and Regulations . . . . .	38
CHAPTER 3	Quality Management in the Clinical Laboratory . . . . .	57
CHAPTER 4	Analytic Techniques . . . . .	90
CHAPTER 5	Clinical Chemistry Automation . . . . .	129





## CHAPTER 1

© Yurchanka Siarhei/Shutterstock.

# Basic Principles and Practices of Clinical Chemistry

Kathryn Dugan and Elizabeth Warning

## CHAPTER OUTLINE

---

### Units of Measure

#### Reagents

- Chemicals
- Reference Materials
- Water Specifications
- Solution Properties
- Concentration
- Colligative Properties
- Redox Potential
- Conductivity
- pH and Buffers

#### Laboratory Equipment

- Heating Units
- Glassware and Plasticware
- Desiccators and Desiccants
- Balances
- Centrifuges

### Laboratory Mathematics and Calculations

- Significant Figures
- Logarithms
- Concentration
- Dilutions
- Simple Dilutions
- Serial Dilutions
- Water of Hydration
- Graphing and Beer's Law

### Specimen Collection and Handling

- Types of Samples
- Sample Processing
- Sample Variables
- Chain of Custody
- Electronic and Paper Reporting of Results

### References

## KEY TERMS

---

- Analyte
- Anhydrous
- Arterial blood
- Beer's law
- Buffer
- Calibration
- Centrifugation
- Cerebrospinal fluid (CSF)
- Colligative property
- Conductivity
- Deionized water
- Delta absorbance

- Density
- Desiccant
- Dilution
- Distilled water
- Equivalent weight
- Erlenmeyer flasks
- Filtration
- Graduated cylinder
- Griffin Beaker
- Hemolysis
- Henderson-Hasselbalch equation
- Hydrate

- Hygroscopic
- Icterus
- International unit
- Ionic strength
- Linearity
- Lipemia
- Molality
- Molarity
- Normality
- One-point calibration
- Osmotic pressure
- Oxidized

Oxidizing agent	Reducing agent	Specific gravity
Percent solution	Reverse osmosis	Standard reference materials (SRMs)
pH	Serial dilution	Système International d'Unités (SI)
Pipette	Serum	Thermistor
Primary standard	Significant figures	Valence
Reagent-grade water	Solute	Volumetric
Redox potential	Solution	Whole blood
Reduced	Solvent	

## CHAPTER OBJECTIVES

Upon completion of this chapter, the clinical laboratorian should be able to do the following:

- Convert results from one unit format to another using the SI and traditional systems.
- Describe the classifications used for reagent-grade water.
- Identify the varying chemical grades used in reagent preparation and indicate their correct use.
- Define primary standard and standard reference materials.
- Describe the following terms that are associated with solutions and, when appropriate, provide the respective units: percent, molarity, normality, molality, saturation, colligative properties, redox potential, and conductivity.
- Compare and contrast osmolarity and osmolality.
- Define a buffer and give the formula for pH and pK calculations.
- Use the Henderson-Hasselbalch equation to determine the missing variable when given either the pK and pH or the pK and concentration of the weak acid and its conjugate base.
- List and describe the types of thermometers used in the clinical laboratory.
- Classify the type of pipette when given an actual pipette or its description.
- Demonstrate the proper use of a measuring and volumetric pipette.
- Describe two ways to calibrate a pipetting device.
- Define a desiccant and discuss how it is used in the clinical laboratory.
- Describe how to properly care for and balance a centrifuge.
- Correctly perform the laboratory mathematical calculations provided in this chapter.
- Identify and describe the types of samples used in clinical chemistry.
- Outline the general steps for processing blood samples.
- Apply Beer's law to determine the concentration of a sample when the absorbance or change in absorbance is provided.
- Identify the preanalytic variables that can adversely affect laboratory results as presented in this chapter.

## CASE STUDY 1.1, PART 1

Meet Miles, a 25-year-old graduate who accepted his first job offer working in the chemistry department at a large medical center. Miles and Mía were classmates in college and often support each other on technical issues, even though they work at different facilities within the same health system.



© dotshock/Shutterstock.

## CASE STUDY 1.2, PART 1

Meet Mía, a 35-year-old graduate who is also newly hired and works as a generalist in a small community hospital. Mía received a rainbow of tubes from the emergency department. She handed her coworker the lavender- and blue-top tubes and placed the 8.0-mL plain red-top tube and the 3.5-mL plasma separator tube in the centrifuge. She placed the heparinized whole blood specimen on the mixer and logged in to the laboratory information system to receive the specimens. Once the specimens were accessioned, she ran a STAT profile on the Nova pH0x analyzer using the whole blood specimen, and the results were autoverified.



© Ariel Skelley/DigitalVision/Getty Images.

The primary purpose of a clinical chemistry laboratory is to perform analytic procedures that yield accurate and precise information, aiding in patient diagnosis and treatment. The achievement of reliable results requires that the clinical laboratorian be able to correctly use basic supplies and equipment and possess an understanding of fundamental concepts critical to any analytic procedure. The topics in this chapter include units of measure, basic laboratory supplies, and introductory laboratory mathematics, plus a brief discussion of specimen collection, processing, and reporting.

## Units of Measure

Any meaningful *quantitative* laboratory result consists of two components: the first component represents the number related to the actual test value, and the second is a label identifying the units. The unit defines the physical quantity or dimension, such as mass, length, time, or volume.<sup>1</sup> There are a few laboratory tests that do not have units, but whenever possible, units should be used.

The **Système International d'Unités (SI)** was adopted in 1960. It is preferred in scientific literature and clinical laboratories and is the only system employed in many countries. This system was devised to provide the global scientific community with a uniform method of describing physical quantities. The SI system units (referred to as *SI units*) are based on the metric system. Several subclassifications exist within the SI system, one of which is the *basic unit*. There are seven basic units (**Table 1.1**), with length (meter), mass (kilogram), and quantity of a substance (mole) being the units most frequently encountered. Derived units are another subclassification of the SI system. A derived unit is a mathematical function describing one of the basic units. An example of an SI-derived unit is meters per second (m/s), which is used to express velocity. Some non-SI units are so widely used that they have become acceptable for use within the SI system (Table 1.1). These include units such as hour, minute, day, gram, liter, and plane angles expressed as degrees. The SI system uses standard prefixes to indicate a decimal fraction or multiples of that basic unit (**Table 1.2**).<sup>1</sup> For example, 0.001 liter can be expressed using the prefix *milli*, or  $10^{-3}$ , and since it requires moving the decimal point three places to the right, it can then be written as 1 milliliter, or abbreviated as 1 mL. It may also be written in scientific notation as  $1 \times 10^{-3}$  L. Likewise, 1000 liters would use the prefix of kilo ( $10^3$ ) and could be written as 1 kiloliter

**Table 1.1** SI Units

Base Quantity	Name	Symbol
Length	Meter	m
Mass	Kilogram	kg
Time	Second	s
Electric current	Ampere	A
Thermodynamic temperature	Kelvin	K
Amount of substance	Mole	mol
Luminous intensity	Candela	cd
<b>Selected Derived</b>		
Frequency	Hertz	Hz
Force	Newton	N
Celsius temperature	Degree Celsius	°C
Catalytic activity	Katal	kat
<b>Selected Accepted Non-SI</b>		
Minute (time)	(60 s)	min
Hour	(3600 s)	h
Day	(86,400 s)	d
Liter (volume)	(1 dm <sup>3</sup> = 10 <sup>-3</sup> m <sup>3</sup> )	L
Angstrom	(0.1 nm = 10 <sup>-10</sup> m)	Å

© Jones & Bartlett Learning.

or expressed in scientific notation as  $1 \times 10^3$  L. Table 1.2 indicates prefixes that are frequently used in clinical laboratories. Prefixes smaller than the basic unit have a negative exponent (deci:  $10^{-1}$ ), and prefixes larger than the base unit have a positive exponent (kilo:  $10^3$ ). When converting between prefixes, note the relationship between the two prefixes based on whether you are changing to a smaller or larger prefix. When converting from a larger to smaller, the decimal will move to the right. For example, converting one liter ( $1.0 \times 10^0$  or 1.0) to milliliters ( $1.0 \times 10^{-3}$  or 0.001), the starting unit (L) is larger than milliliters, by a factor of 1000, or  $10^3$ . This means that the decimal place moves to the *right* three places, so 1.0 liter (L) equals 1000 milliliters (mL). The opposite is also true. When converting to a larger unit, the decimal place moves to the left. For example, converting 1000 milliliters (mL) to 1.0 liter (L), the decimal

## SI CONVERSIONS

To convert between SI units, move the decimal the difference between the exponents represented by the prefix of the base unit. When moving from a larger unit to a smaller unit, the decimal will move to the right. When converting from a smaller unit to a larger unit, the decimal will move to the left.

If converting from smaller unit to larger unit, then move decimal to the left the exponent difference.

If converting from larger unit to smaller unit, then move decimal to the right the exponent difference.

point moves to the *left* three places to become 1.0 L. Note that the SI term for mass is *kilogram*, which is the only basic unit that contains a prefix as part of its name. Generally, the clinical laboratory uses the term *gram* for mass rather than *kilogram*.

### Example 1: Convert 1.0 L to $\mu\text{L}$

$$1.0 \text{ L } (1 \times 10^0) \\ \mu\text{L (micro} = 10^{-6})$$

The difference between the exponents = 6. The conversion is from a larger unit to a smaller unit, so the decimal will move 6 places to the right.

$$1.0 \text{ L} = 1,000,000 \mu\text{L}$$

### Example 2: Convert 5 mL to $\mu\text{L}$

$$5 \text{ mL (milli} = 10^{-3}) \\ \mu\text{L (micro} = 10^{-6})$$

The difference between the exponents = 3. The conversion is from a larger unit to a smaller unit, so the decimal will move 3 places to the right.

$$5 \text{ mL} = 5000 \mu\text{L}$$

**Table 1.2** Prefixes Used with SI Units

Factor	Prefix	Symbol	
$10^{-18}$	atto	a	0.000000000000000001
$10^{-15}$	femto	f	0.000000000000001
$10^{-12}$	pico	p	0.000000000001
$10^{-9}$	nano	n	0.000000001
$10^{-6}$	micro	$\mu$	0.000001
$10^{-3}$	milli	m	0.001
$10^{-2}$	centi	c	0.01
$10^{-1}$	deci	d	0.1
$10^0$	Liter, meter, gram	Basic unit	1.0
$10^1$	deca	da	10
$10^2$	hecto	h	100
$10^3$	kilo	k	1000
$10^6$	mega	M	1,000,000
$10^9$	giga	G	1,000,000,000
$10^{12}$	tera	T	1,000,000,000,000
$10^{15}$	peta	P	1,000,000,000,000,000
$10^{18}$	exa	E	1,000,000,000,000,000,000

Prefixes are used to indicate a subunit or multiple of a basic SI unit.

© Jones & Bartlett Learning.



**Example 3: Convert 5.3 mL to dL**

$$5.3 \text{ mL (milli} = 10^{-3})$$

$$\text{dL (deci} = 10^{-1})$$

The conversion is moving from a smaller unit to a larger unit, so the decimal place will move two places to the left.

$$5.3 \text{ mL} = 0.053 \text{ dL}$$

Reporting of laboratory results is often expressed in terms of substance concentration (e.g., moles) or the mass of a substance (e.g., mg/dL, g/dL, g/L, mmol/L, and IU) rather than in SI units. These traditional units can cause confusion during interpretation and conversion to SI units: examples of conversions can be found later in the chapter. As with other areas of industry, the laboratory and the rest of medicine are moving toward adopting universal standards promoted by the International Organization for Standardization, often referred to as ISO. This group develops standards of practice, definitions, and guidelines that can be adopted by everyone in a given field, providing for more uniform terminology. Many national initiatives have recommended common units for laboratory test results, but none have been widely adopted.<sup>2</sup> As with any transition, the clinical laboratorian should be familiar with all the terms currently used in their field and how to convert these to SI units.

**Reagents**

In today's highly automated laboratory, there is little need for reagent preparation by the laboratorian. Most instrument manufacturers make the reagents in a ready-to-use form or "kit" in which all necessary reagents and respective storage containers are prepackaged as a unit, requiring only the addition of water or buffer for reconstitution. A heightened awareness of the hazards of certain chemicals and the numerous regulatory agency requirements has caused clinical chemistry laboratories to eliminate massive stocks of chemicals and opt instead for the ease of using prepared reagents. Periodically, the laboratorian may still need to prepare reagents or solutions, especially in hospital laboratories involved in research and development, biotechnology applications, specialized analyses, or method validation.

**Chemicals**

Analytic chemicals exist in varying grades of purity: Reagent grade or analytic reagent (AR); ultrapure, chemically pure (CP); United States Pharmacopeia (USP); National Formulary (NF); and technical or commercial grade.<sup>3</sup> Chemicals with AR designation are suitable for use in most analytic laboratory procedures. A committee of the American Chemical Society (ACS) established specifications for AR grade chemicals, and chemical manufacturers must either meet or exceed these requirements. The labels on reagents should clearly state the actual impurities for each chemical lot or list the maximum allowable impurities. The label should also include one of the following designations: AR or ACS or *For laboratory use* or *ACS Standard-Grade Reference Materials*. Ultrapure chemicals have additional purification steps for use in specific procedures such as chromatography, immunoassays, molecular diagnostics, standardization, or other techniques that require extremely pure chemicals. These reagents may have designations of HPLC (high-performance liquid chromatography) or chromatographic on their labels.

Because USP- and NF-grade chemicals are used to manufacture drugs, the limitations established for this group of chemicals are based only on the criterion of not being injurious to individuals. Chemicals in this group may be pure enough for use in most chemical procedures, but the purity standards they meet are not based on the needs of the laboratory and may or may not meet all assay requirements.

Reagent designations of CP or ultrapure grade indicate that the impurity limitations are not stated, and preparation of these chemicals is not uniform. It is not recommended that clinical laboratories use these chemicals for reagent preparation unless further purification or a reagent blank is included. Technical or commercial grade reagents are used primarily in manufacturing and should never be used in the clinical laboratory.

Organic reagents also have varying grades of purity that differ from those used to classify inorganic reagents. These grades include a practical grade with some impurities; CP, which approaches the purity level of reagent-grade chemicals; spectroscopic (spectrally pure) and chromatographic grade organic reagents; and reagent grade (ACS), which is certified to contain impurities below established ACS levels. Other than the purity aspects of the chemicals, laws related to the Occupational Safety and Health Administration (OSHA)<sup>4</sup> require manufacturers to indicate any physical or biologic health

hazards and precautions needed for the safe use, storage, and disposal of any chemical. Manufacturers are required to provide a Safety Data Sheet (SDS). A copy of the SDS must be readily available to ensure the safety of laboratorians.

## Reference Materials

Unlike other areas of chemistry, clinical chemistry is involved in the analysis of biochemical by-products found in *biological* fluids, such as serum, plasma, or urine. For this reason, traditionally defined standards used in analytical chemistry do not readily apply in clinical chemistry.

A **primary standard** is a highly purified chemical that can be measured directly to have an *exact* known concentration and purity. The ACS has purity tolerances for primary standards; because most biologic constituents are unavailable within these tolerance limitations, the National Institute of Standards and Technology (NIST) has certified **standard reference materials (SRMs)** that are used in place of ACS primary standard materials.<sup>5-7</sup>

These SRMs are assigned a value after analysis using state-of-the-art methods and equipment. The chemical composition of these substances is then certified; however, they may not have the purity of a primary standard. Because each substance has been characterized for certain chemical or physical properties, it can be used in place of an ACS primary standard in clinical work and is often used to verify **calibration** or accuracy/bias assessments. Many manufacturers use a NIST SRM when producing calibrator and standard materials. These materials are considered “traceable to NIST” and may meet certain accreditation requirements. Standard reference materials are used for **linearity** studies to determine the relationship between the standard’s concentration and the instrument result. Linearity studies are required when a new test or new test methodology is introduced. There are SRMs for a number of routine analytes, hormones, drugs, and blood gases, with others being added.<sup>5</sup> Calibration of an instrument is a process that pairs an analytical signal with a concentration value of an analyte. When performing a calibration, a series of calibrators with known concentrations of a specific analyte are used. The instrument is programmed with the known concentrations and will adjust the analytic signal to match the given concentration. Calibrators can be purchased as a kit or made by diluting a known stock solution.

## Water Specifications<sup>8</sup>

Water is the most frequently used reagent in the laboratory. Tap water is unsuitable for laboratory applications. Most procedures, including reagent and control preparation, require water that has been substantially purified, known as **reagent-grade water**. There are various water purification methods including distillation, ion exchange, reverse osmosis, ultrafiltration, ultraviolet light, sterilization, and ozone treatment. According to the Clinical and Laboratory Standards Institute (CLSI), reagent-grade water is classified into one of six categories based on the specifications needed for its use rather than the method of purification or preparation.<sup>9</sup> These categories include clinical laboratory reagent water (CLRW), special reagent water (SRW), instrument feed water, water supplied by method manufacturer, autoclave and wash water, and commercially bottled purified water. Each category has a specific acceptable limit. The College of American Pathologists requires laboratories to define the specific type of water required for each of its testing procedures and requires water quality testing at least annually. Water quality testing routinely includes monitoring microbial colony-forming units/mL and may also include other parameters.

**Distilled water** has been purified to remove almost all organic materials, using a technique of distillation where water is boiled and vaporized. Many impurities do not rise in the water vapor and will remain in the boiling apparatus so that the water collected after condensation has less contamination. Water may be distilled more than once, with each distillation cycle removing additional impurities. Ultrafiltration and nanofiltration, like distillation, are excellent in removing particulate matter, microorganisms, and any pyrogens or endotoxins.

**Deionized water** has some or all ions removed, although organic material may still be present, so it is neither pure nor sterile. Generally, deionized water is purified from previously treated water, such as prefiltered or distilled water. Deionized water is produced using either an anion- or a cation-exchange resin, followed by replacement of the removed ions with hydroxyl or hydrogen ions. A combination of several ion-exchange resins will produce different grades of deionized water. A two-bed system uses an anion resin followed by a cation resin. The different resins may be in separate columns or in the same column. This process is excellent at removing dissolved ionized solids and dissolved gases.

**Reverse osmosis** is a process that uses pressure to force water through a semipermeable membrane, producing a filtered product. Reverse osmosis may be used for the pretreatment of water, however, it does not remove dissolved gases.

**Filtration** can remove particulate matter from municipal water supplies before any additional treatments. Filtration cartridges can be composed of glass, cotton, or activated charcoal, which removes organic materials and chlorine. Some have submicron filters ( $\leq 0.2 \mu\text{m}$ ), which remove any substances larger than the filter's pores, including bacteria. The use of these filters depends on the quality of the municipal water and the other purification methods used. For example, hard water (containing calcium, iron, and other dissolved elements) may require prefiltration with a glass or cotton filter rather than activated charcoal or submicron filters, which quickly become clogged and are expensive to use. The submicron filter may be better suited after distillation, deionization, or reverse osmosis treatment.

Ultraviolet oxidation, which removes some trace organic material or sterilization processes at specific wavelengths, can destroy bacteria when used as part of a system but may leave behind some residual products. This technique is often followed by other purification processes.

Reagent-grade water can be obtained by initially filtering to remove particulate matter, followed by reverse osmosis, deionization, and a  $0.2\text{-}\mu\text{m}$  filter or more restrictive filtration process. Autoclave wash water is acceptable for glassware washing but not for analysis or reagent preparation. SRW is used for specific techniques like the HPLC, molecular diagnostics, or mass spectrophotometry, which may require specific parameters for the analysis. All SRW should meet CLRW standards and, depending on the application, CLRW should be stored in a manner that reduces any chemical or bacterial contamination and for short periods.

Testing procedures to determine the quality of reagent-grade water include measurements of resistance, pH, colony counts on selective and nonselective media for the detection of bacterial contamination, chlorine, ammonia, nitrate or nitrite, iron, hardness, phosphate, sodium, silica, carbon dioxide, chemical oxygen demand, and metal detection. Some accreditation agencies<sup>10</sup> recommend that laboratories document culture growth, pH, and specific resistance on water used in reagent preparation. Resistance is measured because pure water, devoid of ions, is a poor conductor of electricity and has increased resistance. The relationship of water purity to resistance is linear; generally, as purity increases, so does resistance.

This one measurement does not suffice for determination of true water purity because a nonionic contaminant may be present that will have little effect on resistance. Reagent water meeting specifications from other organizations, such as the American Society for Testing and Materials (ASTM), may not be equivalent to those established by the CLSI, so care should be taken to meet the assay procedural requirements for water type.

## Solution Properties

In clinical chemistry, substances found in biologic fluids, including serum, plasma, urine, and spinal fluid, are quantified. A substance that is dissolved in a liquid is called a **solute**; a biologic solute is also known as an **analyte**. The liquid in which the solute is dissolved—for example, a biologic fluid—is the **solvent**. Together, solute and solvent represent a **solution**. Any chemical or biologic solution can be described by its basic properties, including concentration, saturation, colligative properties, redox potential, conductivity, density, pH, and ionic strength.

## Concentration

The analyte concentration in solution can be expressed in many ways. Concentration is commonly expressed as *percent solution*, *molarity*, *molality*, or *normality*. These are non-SI units, however; the SI unit for the amount of a substance is the *mole*. Examples of concentration calculations are provided later in this chapter.

**Percent solution** is expressed as the amount of solute per 100 total units of solution. Three expressions of percent solutions are weight per weight (w/w), volume per volume (v/v), and weight per volume (w/v). Weight per weight (% w/w) refers to the number of grams of solute per 100 g of solution. Volume per volume (% v/v) is used for liquid solutes and gives the milliliters of solute in 100 mL of solution. For v/v solutions, it is recommended that grams per deciliter (g/dL) be used instead of % v/v. Weight per volume (% w/v) is the most commonly used percent solution in the clinical laboratory and is defined as the number of grams of solute in 100 mL of solution. Weight per volume is not the same as molarity, and care must be taken to not confuse the two. Examples of percent solution calculations can be found later in this chapter.

**Molarity (M)** is expressed as the number of moles per 1 L of solution. One mole of a substance equals its gram molecular weight (gmw), so the customary units of molarity (M) are moles/liter. The SI representation for the traditional molar concentration is moles

of solute per volume of solution, with the volume of the solution given in liters. The SI expression for concentration should be represented as moles per liter (mol/L), millimoles per liter (mmol/L), micromoles per liter ( $\mu\text{mol/L}$ ), or nanomoles per liter (nmol/L). The common concentration term *molarity* is not an SI unit for concentration. Molarity depends on volume, and any significant physical changes that influence volume, such as changes in temperature and pressure, will also influence molarity. Calculations can be found in the Laboratory Mathematics and Calculations section of this chapter.

**Molality (m)** represents the amount of solute per 1 kg of solvent. Molality is sometimes confused with molarity; however, it can be easily distinguished because molality is always expressed in terms of moles per kilogram (weight per weight) and describes moles per 1000 g (1 kg) of solvent. Note that the common abbreviation (m) for molality is a lowercase “m,” while the uppercase “M” refers to molarity. Molality is not influenced by temperature or pressure because it is based on mass rather than volume.

**Normality** is the least likely of the four concentration expressions to be encountered in clinical laboratories, but it is often used in chemical titrations and chemical reagent classification. It is defined as the number of gram equivalent weights per 1 L of solution. An **equivalent weight** is equal to the gmw of a substance divided by its valence. The **valence** is the number of units that can combine with or replace 1 mole of hydrogen ions for acids and hydroxyl ions for bases and the number of electrons exchanged in oxidation–reduction reactions. Normality is always equal to or greater than the molarity of the compound. Calculations can be found later in this chapter. Normality was previously used for reporting electrolyte values, expressed as milliequivalents per liter (mEq/L); however, this convention has been replaced with millimoles per liter (mmol/L). The College of American Pathologists (CAP) currently requires chloride to be reported in mmol/L. Because the four main electrolytes,  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{CO}_2^-$  ( $\text{HCO}_3^-$ ), and  $\text{Cl}^-$ , all have a valence of 1, the concentration reported will remain the same whether the unit is mEq/L or mmol/L.

Solution saturation gives little specific information about the concentration of solutes in a solution. A solution is considered *saturated* when no more solvent can be dissolved in the solution. Temperature, as well as the presence of other ions, can influence the solubility constant for a solute in a given solution and thus affect the saturation. Routine terms in the clinical laboratory that describe the extent of saturation are *dilute*, *concentrated*, *saturated*, and *supersaturated*.

A *dilute solution* is one in which there is relatively little solute or one that has a lower solute concentration per volume of solvent than the original, such as when making a dilution. In contrast, a *concentrated solution* has a large quantity of solute in solution. A solution in which there is an excess of undissolved solute particles can be referred to as a *saturated solution*. As the name implies, a *supersaturated solution* has an even greater concentration of undissolved solute particles than a saturated solution of the same substance. Because of the greater concentration of solute particles, a supersaturated solution is thermodynamically unstable. The addition of a crystal of solute or mechanical agitation disturbs the supersaturated solution, resulting in crystallization of any excess material out of solution. An example is when measuring serum osmolality by freezing point depression.

## Colligative Properties

Colligative properties are those properties related to the number of solute particles per solvent molecules, not on the type of particles present. The behavior of particles or solutes in solution demonstrates four properties: **osmotic pressure**, vapor pressure, freezing point, and boiling point. These are called **colligative properties**. *Osmotic pressure* is the pressure that opposes osmosis when a solvent flows through a semipermeable membrane to establish equilibrium between compartments of differing concentration. *Vapor pressure* is the pressure exerted by the vapor when the liquid solvent is in equilibrium with the vapor. *Freezing point* is the temperature at which the first crystal (solid) of solvent forms in equilibrium with the solution. *Boiling point* is the temperature at which the vapor pressure of the solvent reaches atmospheric pressure (usually 1 atmosphere).

The osmotic pressure of a dilute solution is directly proportional to the concentration of the molecules in solution. The expression for concentration is the osmole. One osmole of a substance equals the molarity or molality multiplied by the number of particles, not the kind of particle, at dissociation. If molarity is used, the resulting expression would be termed osmolarity; if molality is used, the expression changes to osmolality. Osmolality is preferred since it depends on the weight rather than volume and is not readily influenced by temperature and pressure changes. When a solute is dissolved in a solvent, the colligative properties change in a predictable manner for each osmole of substance present. In the clinical setting, freezing point and vapor pressure depression can be measured as a function